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A marked and selective decrease in the overall expression of the calcium-binding
protein, parvalbumin (PV), has been a consistent postmortem finding in patients with
schizophrenia. The documented reduction in calcium-binding protein immunoreactivity
is specific to PV, and is observed exclusively within the prefrontal cortex and
hippocampus (HPC) of patients. Models of schizophreniform cognitive dysfunction
induced by chronic NMDA-receptor hypofunction utilizing non-competitive NMDA
antagonist drugs such as ketamine (KET), have been shown to show comparable
decreases in HPC and prefrontal cortical PV expression. Down-regulation of PV
immunoreactivity within these key brain regions associated with cognition is often
considered to be a marker for underlying neural pathology. However, contradictory
findings are present in the literature, with some groups reporting decreased, increased,
or no change in PV expression following comparable NMDA antagonist treatments.
Upon examining methodology across studies, it is clear that inconsistencies, particularly
with regard to the age of subjects, time of tissue collection, and treatment-induced
behavioral impairments as related to PV outcomes. In order to better understand the
distinct roles of these factors on PV expression, the present set of studies within this
dissertation sought to elucidate upon the following: 1) age-dependent baseline
regulation of PV expression; 2) effect of chronic KET treatment (30 mg/kg IP; 14
consecutive days) on cognitive performance in a spatial memory task; 3) effect of

chronic KET treatment on PV expression, and its relationship to observed cognitive
impairment; and 4) the interaction between age and KET administration on PV
expression. The findings presented herein provide evidence suggesting a dynamic
interaction between age and chronic KET treatment on overall PV expression within
HPC and neocortical regions. Based on our data, we propose that PV expression is a
highly dynamic neuronal marker, which can be modulated based on a myriad of factors
(e.g. age, experience, treatment, etc.). Taken together, the findings from the present
work suggest that changes in PV expression following NMDA antagonist treatment
should be considered in the context of age, and that PV may not be an accurate or
translational marker of pathological dysfunction.
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CHAPTER 1
Introduction
1.1

Schizophrenia

Schizophrenia (SCZ) is a debilitating and complex psychiatric illness which affects
approximately 1% of the global population. It is often characterized by its positive
symptoms including hallucination and delusions, as well as negative symptoms such as
an overall flattened affect and deficits in social interactions (Kay et al., 1987; Schultz et
al., 2007). Notably, patients with SCZ also suffer from marked and pervasive deficits in
both attention and cognition (e.g., working memory, spatial navigation, episodic
memory, etc.), which are directly linked to functional outcomes and overall quality of life
(Tamminga et al., 1998; Reichenberg, 2010; Carbon & Correll, 2014). As theories
regarding the etiology of SCZ have evolved, novel approaches into understanding the
developmental trajectory of neuropathological changes within key brain circuits has
become a topic of interest (Insel, 2010), especially with regard to neural circuits that
exhibit dynamic changes across the lifespan (Swann et al., 1989; Watanabe et al.,
1992; Lujan et al., 2005). In order to better understand these impairments, and thus
foster development of novel cognitive-targeting interventions, a more comprehensive
understanding of the neurobiology of forebrain circuits that support the cognitive
processes altered in SCZ is warranted.
The neural pathophysiology underlying symptoms is poorly understood and
theories regarding root mechanisms have shifted since the initial dopaminergic
hypothesis prevalent in the mid-to-late 20th century to more glutamatergic-centric
hypotheses (Carlsson et al., 2001; Sodhi et al., 2008). In support of this advancement in
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understanding, emerging research into pathological dysfunction within key brain circuits
associated with SCZ cognitive deficits have centered on both glutamatergic (Kantrowitz
and Javitt, 2010) and GABAergic (Gonzalez-Burgos et al., 2011) circuitry within the
neocortex and hippocampus (HPC). In fact, HPC circuitries, as well as HPC-cingulate
cortical circuit systems, are thought to be altered at both macro- (e.g. regional
interconnections) and micro- (e.g. local inhibition onto pyramidal cells) levels (Benes,
2000). Afferent and efferent connections between the dorsolateral prefrontal cortex
(DLPFC) and HPC are also thought to be altered, thereby contributing to deficits seen
during cognitive processes that require the manipulation and temporal and/or spatial
encoding of information (Meyer-Lindenberg et al., 2005). Furthermore, local inhibitory
circuitry within the HPC has been found to be altered at the synaptic level (e.g. aberrant
functionality and synaptic connections) which contributes to widespread cognitive
dysfunction (Harrison, 2004). Within these circuits, we are particularly interested in
changes seen in GABAergic local circuit networks, as they are critical in regulating
cognitive and memory processes (Buzsaki & Chrobak, 1995).
1.1.1 Postmortem neuropathology
Investigations into neuropathology in postmortem human brain tissue of patients with
SCZ have revealed abnormalities in structure, as well distinct biological markers, which
have given us insight into the possible underlying mechanisms and trajectory of SCZ
cognitive dysfunction. Overall, these findings have propelled the advancement of
modeling techniques used in rodents to selectively study these putative factors to better
understand their role in the perseveration of the SCZ phenotype (Schmitt et al., 2011;
Benes, 2015). Studies characterizing postmortem tissue of patients with SCZ have
2

revealed both gross and focal anatomical changes in cortical circuits, including the HPC
and prefrontal cortex that are integral to higher order cognitive processes. Selective
reductions of grey matter volume within the prefrontal cortex (Buchanan et al., 1998), as
well as within the HPC (Guo et al., 2014) have been reported, and these findings have
been linked to cognitive disturbances (Buckley, 2005; Wolf et al., 2008). Researchers
have repeatedly characterized significant increases in overall ventricular size,
particularly within the lateral ventricles, which coincides with decreased overall temporal
lobe volume (for review, see McCarley et al., 1999). White matter tracts have are also
impacted in schizophrenic postmortem brains (Davis et al., 2003), indicating a decrease
in the overall connectivity between brain regions, thereby severely limiting cooperative
transfer of information.
Alterations in activation seen during neuroimaging studies in DLPFC are likely
due to dysfunctional neuronal activity. Specifically, a decrease in GABAergic
neurotransmission, and consequently decreased inhibition of excitatory pyramidal
neurons; conversely, even increased inhibition due to compensatory up-regulation of
GABA receptors have been described (Volk & Lewis, 2002; Gonzalez-Burgos & Lewis,
2008; Lisman et al., 2008). Of particular note, the selective decrease of parvalbumin
(described in detail later) expression within inhibitory GABAergic neurons, especially
within prefrontal cortex and HPC, is thought to play a key role in these observed
alterations (Lewis et al., 1999; Hashimoto et al., 2003; Lewis et al., 2004). Disrupted
signaling within this circuit is likely the driving force behind deficits, and therefore
GABAergic neurons are being considered as targets for possible cognitive-enhancing
treatments (Lewis et al., 2005).
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In addition to gross anatomical and circuit-level abnormalities, postmortem
investigations have also suggested distinct focal changes at the neuronal level: both in
neuronal organization, as well as in overall neural morphology (Arnold, 2000; Chana et
al., 2003), which may indicate a neurodevelopmental trajectory for the disorder (Fatemi
& Folsom, 2009). Within the HPC, there is evidence for altered and disorganized
laminar organization of pyramidal neurons (Conrad et al., 1991), which is likely due to
disruption in migration during development (Conrad & Scheibel, 1987). Additionally,
researchers have observed decreases in HPC (e.g., Arnold et al., 1995), and prefrontal
cortical layer 3 (e.g., Pierri et al., 2001) neuron size in SCZ patients. Morphological
changes in neurons within the HPC and prefrontal cortex likely stem from early fetal
insults (e.g., Meyer & Feldon, 2009), genetic abnormalities (e.g., Kamiya et al., 2005),
or even some combination of biological and environmental factors (e.g., Yuii et al.,
2007), which disrupt neuronal migration and maturation (Bunney et al., 1995; Lewis &
Levitt, 2002).
Interestingly, many of the characteristic morphological changes seen in SCZ
neuropathology are associated with subsets of GABAergic inhibitory neurons and
glutamatergic pyramidal cells. Such changes include decreases in the level of
glutamatergic receptor subunits GluR1 and GluR2 on GABAergic neurons within the
prefrontal cortex of patients (Corti et al., 2011); as well as decreases in the overall
number of dendritic spines on cortical glutamatergic pyramidal cells (Glantz & Lewis,
2000). Considerable focus has recently been placed on select alterations in GABAergic
neurons expressing the calcium-binding protein (CBP) parvalbumin (PV), which is
detailed below. Why forebrain PV-expressing GABAergic neurons would be selectively
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disrupted is unclear, although evidence presented within this dissertation (specifically,
chapters 2 and 5) suggest developmental changes in PV expression that perhaps make
these neurons vulnerable to dysfunction.

1.2

Parvalbumin

PV is one of the primary CBPs located in the brain, and is highly expressed in specific
subpopulations of GABAergic neurons. In addition to PV, additional CBPs include
calretinin, calmodulin, and calbindin (Freund & Buzsaki, 1996; Markram et al., 2004),
though particular emphasis is placed on PV-expressing GABAergic neurons due to the
selective decrease in this subpopulation, without concomitant changes in other CBP
expression, in SCZ postmortem tissue (Reynolds et al., 2004). PV expressing
GABAergic inhibitory neurons are located relatively diffusely throughout most, if not all,
brain regions but exhibit distinct morphological characteristics as well as specified
laminar distribution within the neocortex and HPC (Freund & Buzsaki, 1996; Hof et al.,
1999). PV expression can be seen in three primary GABAergic cell types, which include
chandelier cells, basket cells, and O-LM cells (which are specifically located in stratum
oriens in the HPC; Klausberger, 2009). Chandelier cells are primarily located in cortical
layers II-VI, as well as within the HPC (though here they are often referred to as axoaxonic or bistratified cells), and have axonal terminations exclusively on the axon initial
segment of excitatory pyramidal neurons (Markram et al, 2004). Though there are
relatively few of this cell type compared to other inhibitory interneurons, these are
thought to be very powerful with regard to their ability to regulate neural transmission in
the brain (Woodruff et al., 2010). Due to their inhibition directly onto the axon initial
5

segment, chandelier cells also play an important role in regulating pyramidal cell
excitatory output (Lewis et al., 2004). The unique ability for a single chandelier cell to
target large populations of pyramidal neurons allows for wide-spread synchronization of
excitatory transmission (Cobb et al., 1995).
Within the CA1 region of the HPC, basket cells and chandelier cells make up
approximately 75% of the total inhibitory neuron population (Szilagyi et al., 2011). The
anatomical distribution of PV expressing inhibitory neurons within each sub-region of
the HPC (CA1, CA3, dentate gyrus) appears to be consistent in laminar profile across
the septotemporal axis, and shows no septotemporal variation in expression within the
HPC sub-regions in the rat (Kosaka et al, 1987; Nomura et al, 1997a; 1997b). Basket
cells, which are located within the cortex, HPC, and cerebellum (Seto-Ohshima et al.,
1989), synapse onto pyramidal cell somata, as well as their proximal dendrites, and are
located primarily within the HPC pyramidal and granule cell layers (Nitsch et al., 1990;
Freund & Buzsaki, 1996). Similar to chandelier cells, a single PV-containing basket cell
has the ability to make a large number of connections onto local pyramidal neurons, as
well as synapsing with other PV-expressing neurons (Sik et al, 1995), thereby giving
them the ability to strongly modulate postsynaptic excitatory output (Aradi et al., 2002).
PV expressing cells are also located outside of the pyramidal and granule cell layers
within the hilus, as well as within stratum oriens where these PV-expressing neurons
are referred to as O-LM cells (Sloviter, 1989).
A selective decrease in PV immunoreactivity in schizophrenic postmortem tissue
has been a robust finding in the literature, particularly within the prefrontal cortex (e.g.,
Beasley & Reynolds, 1997) and the HPC (e.g., Zhang & Reynolds, 2002). This
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decrease in PV expression suggests an overall decrease in the amount of inhibition
being provided to excitatory postsynaptic pyramidal cells. This decrease in regulatory
inhibition likely puts the system in a state of focal hyperexcitability, which may serve to
distort temporal specificity in neuronal interactions and communication, as well as
create excess neuronal ‘noise’ within neocortical and HPC circuits. Overall, PVcontaining inhibitory neurons play a key role in the regulation of neuronal
communication within and between local circuits in the neocortex and HPC, and
disruption of both local and long-range interactions likely lead to impairment the
accuracy and efficiency of cognitive processing.
1.2.1 Age-related changes
Age-related changes in PV expression have been found in cortical (e.g., Ouda et al.,
2008), as well as subcortical forebrain regions including the HPC (e.g., Vela et al., 2003;
Yamada & Jinno, 2013). However, there have been very few studies offering conclusive
findings outlining age-dependent changes in HPC PV expression in a systematic way. A
paucity of studies have been conducted seeking to directly compare PV expression in
young and aged rats in an attempt to characterize CBP distribution as a function of
developmental age within the HPC, and the literature reveals conflicting findings. There
are findings supporting a decrease in PV expression as a function of age (e.g. Shetty &
Turner, 1998;Lee et al., 2008), as well as those indicating no change in PV expression
across aging (e.g. Kishimoto et al., 1998; Vela et al., 2003; Stanley et al., 2012). Lee
and colleagues (2008) provide evidence for a decrease in PV expression from young (3
months) to aged (6 months), with reduced levels staying stable through 24 months of
age. Shetty and Turner (1998) also describe significant decreases in PV
7

immunoreactivity within HPC CA1, CA3, and hilus between 5- and 24-month old rats,
while Kishimoto and colleagues (1998) describe no change in PV expression within the
HPC as a function of age. Vela and colleagues (2003), as well as Stanley and
colleagues (2012), also describe a lack of age-related effects, though their analyses
only focused on PV expression in adult and aged rats and lacked an adolescent
comparison. The latter studies indicating no change in PV expression as a function of
aging are only exposing a small portion of the lifespan, and it is likely that, had they
included an adolescent time point in their analyses, they would have seen agedependent changes in PV expression in lined with findings from the former studies.
The aforementioned findings, particularly those described in Lee et al. (2008)
describing age-related decreases in PV expression, are in agreement with observation
in our own lab describing an age-related decline in HPC PV expression (Corriveau,
Master’s Thesis, 2013), in addition to findings presented in this dissertation (see
Chapter 2).The lack of systematically conducted normative baseline data regarding PV
distribution across the lifespan is concerning, especially considering that rodent studies
examining PV expression rarely account for the age of the animals used. Furthermore,
the paucity of baseline data makes it difficult to make generalizations based on data
derived from experiments utilizing drug manipulations, as PV immunoreactivity may be
dynamically altered based on a variety of endogenous and exogenous factors including,
but certainly not limited to, age and experience.
1.2.2 Experience-related changes
Experience-related changes in the expression of neuronal and cellular markers (e.g.,
BrdU, NeuN, BDNF, apoptotic markers, etc.) are a well-established phenomenon in the
8

literature (van Praag et al., 2000; Hannan, 2014; Sale et al., 2014). A multitude of
experiences are capability of modulating brain structure and function, including (but not
limited to): maze training (Van der Borght et al., 2005), social interaction (Woolley &
Doupe, 2008); physical stimulation (e.g. stimulation of whiskers; Knott et al., 2002);
sexual experience (Leuner et al., 2010); stress (Zoladz et al., 2012); and environmental
enrichment (Harati et al., 2011). There are few studies which have explicitly examined
the relationship between enrichment and PV expression, but those that have been
reported indicate clear enrichment and/or deprivation-related alterations within sensory
cortices (e.g., Jiao et al., 2006) and HPC (e.g., Iuvone et al., 1996). Iuvone and
colleagues (1996) provide clear evidence of experience-related increases in PV
expression across all HPC sub-regions, which is consistent with our findings in
extensively trained rats in previous studies conducted in our lab (Corriveau, Master’s
Thesis, 2013), in addition to the present work outlined in Chapter 4 of this dissertation.
1.2.3 NMDA antagonist induced changes
Of particular relevance to the selective decrease in PV expression within SCZ
postmortem tissue have been studies employing acute and/or chronic NMDA-antagonist
drug regimens in rodents (e.g. Kittelberger et al., 2012). The administration of
pharmacological substances blocking NMDA receptors (e.g. ketamine (KET); PCP; MK801) has been shown to significantly impact both human and rodent performance in
cognitive tasks involving working (e.g., Driesen et al., 2013), episodic (e.g., Nakazawa
et al., 2003), and spatial memory systems (e.g., Butelman, 1989), with some rodent
studies noting concomitant decreases in PV expression in line with observed behavioral
impairments (e.g. Kittelberger et al., 2012). While studies generally report decreases in
9

overall PV expression as a result of NMDA-antagonist administration (e.g. Romon et al.,
2011; Wang et al., 2008; Braun et al., 2007; Keilhoff et al., 2004), there are some labs
with evidence suggesting no change in PV-immunoreactivity following acute or chronic
NMDA-antagonist pharmacological manipulations (e.g. Benneyworth et al., 2011; Zhang
et al., 2008). Adding another level of complexity, there are some reports of increased
cortical PV expression following NMDA-antagonist treatments (Abdul-Monim et al.,
2007; Sabbagh et al., 2013). These conflicting findings that evidence increases (AbdulMonim et al., 2007), decreases (Keilhoff et al., 2004; Behrens et al., 2007; Braun et al.,
2007; Wang et al., 2008; Romon et al., 2011; Kittelberger et al., 2012), and no
significant effects (Zhang et al., 2008; Benneyworth et al., 2011) following NMDA
antagonist (e.g. KET) administration, raise questions regarding the methodological
preparations employed, as well as the translational validity of the findings. Upon
examination of the aforementioned literature, it becomes clear that age is not controlled
for as a possible factor influencing PV expression. Rather, many of these studies seem
to assume stability in PV expression over the lifespan. A major rationale for the current
set of studies was to examine age-related differences in PV expression, as well as other
possible mediating factors (e.g. cognitive-behavioral experience; tissue collection
timeline) in order to provide clarity to the existing literature and inform future studies
centering on NMDA-antagonist induced changes in neuropathology.
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1.3

Dissertation Purpose

The purpose of the present dissertation was threefold: 1) to provide characterization of
baseline PV expression as a function of age and behavioral experience; 2) to provide
evidence of the dynamic interaction of chronic KET treatment with age and behavioral
experience on cognitive performance on PV expression; and 3) to systematically
describe the mediation of PV expression by interactions between age, time of sacrifice,
and KET administration. Four distinct studies were conducted in order to better
understand and characterize the role of glutamatergic hypofunction on age- and
experience-dependent changes in PV expression that have been previously observed in
our lab. Chapter 1 of this dissertation details the normative developmental distribution of
PV within the HPC, striatum, and neocortex across key milestones in the rat: young (1
month), adult (6 months), and aged (12 months), indicating an overall decrease in
expression with age. Chapter 2 provides evidence for chronic KET-induced disruption of
spatial memory processes in the absence of concomitant changes in HPC and cortical
PV expression. Chapter 3 specifically characterizes impact of KET administration in
both behaviorally naïve and trained rats, indicating a dynamic effect of treatment based
on experience. Finally, chapter 4 provides evidence for an opposing effect of KET
treatment on young (1 month) compared to adult (6 months) rats, in addition to
providing compelling evidence for a recovery of phenotype based on time of sacrifice.
Together, the studies presented herein provide insight into the dynamic nature of PV
expression and its relationship to cognitive performance.
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CHAPTER 2
Evidence for age-dependent and brain region specific changes
in parvalbumin protein expression

2.1

Abstract

A selective decrease in parvalbumin (PV) immunoreactivity is seen in post-mortem
schizophrenic hippocampus and prefrontal cortex. Animal models of schizophreniform
dysfunction following acute and/or chronic ketamine (KET) treatment show comparable
PV decreases. However, there exist conflicting reports with respect to PV
immunoreactivity following sub-chronic KET treatment; calling into question the efficacy
of using PV as a pathological marker. Upon examination of methodology across studies,
it is clear that there are differences in protocols, particularly with regard to age during
treatment and/or sacrifice. Furthermore, the literature lacks a sufficient description of
baseline/ normative PV expression in drug- and behaviorally-naïve tissue. In order to
understand the putative role of PV in pathology, systematic characterization of
normative distribution across ages is warranted. The present study examined PV
expression across the septotemporal axis of the rat hippocampus and in neocortical and
striatal regions in 1, 6, and 12 month old rats. Our findings suggest that hippocampal PV
expression in untreated naïve rats decreases from 1 to 6 months of age, with levels
remaining stable through minimally 12 months of age. Furthermore, we provide
evidence that age-related changes in PV are specific to the hippocampus, as PV
expression remained stable in all cortical and striatal areas examined. Based on our
data, we propose that PV expression is a dynamic marker, and that changes in
expression based on age should be considered when modeling pathology.
12

2.2

Introduction
In reviewing the literature, it is clear that there is a glaring discrepancy in the

ages of rodents used across studies aiming to explore the impact of acute and/or
chronic ketamine (KET) administration on parvalbumin (PV) expression and cognitive
functioning. Despite using similar pharmacological preparations and methods,
Benneyworth and colleagues (2011) found no change in PV expression following KET
administration in young rats, whereas Kittelberger and colleagues (2012) found
significant changes in PV expression following a similar KET protocol. This oversight in
the age of experimental subjects is problematic, as there is evidence of a
developmental shift in NMDA receptor expression and composition across the lifespan
(Law et al., 2003; Cull-Candy et al., 2001; Monyer et al., 1994; Watanabe et al., 1992).
This developmental shift in the pattern of subunit composition likely plays a role in how
impactful NMDA antagonist treatment is, both on underlying biology and on behavior.
This is evidenced in the ability for NMDA antagonists (e.g. MK-801) to block
neurotoxicity in young, but not old, rats (Zhou & Baudry, 2006).
Within normally developing organisms, there is some evidence suggesting that
PV protein expression and distribution may vary as a function of developmental age in
monkeys (Akil and Lewis, 1992) and rodents (Gao et al., 2000; Sanchez et al., 1992).
The findings with respect to PV expression across the lifespan is varied, and evidence
also suggests that there may be species- and strain-related differences in the baseline
levels of PV immunoreactivity across brain regions (Hof et al., 1999 ; Ouda et al., 2008,
respectively). Despite some insight into PV distribution in normally aging animals,
developmental changes in baseline PV expression within normally developing
behaviorally- and pharmacologically-naïve rats have not yet been systematically studied
13

across the lifespan. Notably, characterization of PV expression with respect to distinct
HPC sub-regions and across the septotemporal extent, as well as in cortical regions,
across development is warranted., This baseline characterization is needed to address
1) the gap in the literature regarding normative distribution; 2) the lack of understanding
of the role of PV in development and cognition; and 3) to inform subsequent studies
utilizing PV as a marker of pathology as it relates to psychiatric disorders (i.e. SCZ). To
that end, the current study sought to elucidates upon the expression of PV across the
lifespan of the rat, and herein we provide evidence for a dynamic interaction between
PV expression and developmental age, with particular reference to the HPC formation
and across its septotemporal axis.

2.3

Methods

2.3.1 Subjects
The current study utilized eighteen male Sprague Dawley rats (Charles River
Laboratories, Wilmington, MA) spanning three distinct ages: adolescent (approximate
age P30; referred to as 1 month old; n = 6), young adult (approximate age P120-180;
referred to as 6 months old; n = 6), and adult (approximate age of 12 months old; n = 6).
Adult rats were single-housed, while young rats were pair-housed, in clear
polycarbonate caging with access to food and water ad libitum. All rats were
experimentally and pharmacologically naïve and experienced normal husbandry
procedures within a humidity and temperature controlled vivarium with a 12-hour
light/dark cycle (lights on at 0800h) and arrived to the colony approximately 3 weeks
prior to sacrifice and tissue collection. All housing and experimental procedures were in
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accordance with, and approved by, the University of Connecticut Institutional Animal
Care and Use Committee.
2.3.2 Immunohistochemistry
Rats were anesthetized with Euthasol (pentobarbital sodium solution; 0.5 – 1mL via
intraperitoneal (IP) injections) and transcardially perfused with ice-cold 0.9%
physiological saline solution immediately followed by ice-cold 3.7% paraformaldehyde
solution. Following perfusions, brains were removed and individually stored in
scintillation vials filled with 3.7% paraformaldehyde solution for 1 week. Prior to
sectioning, brains were transferred into a 30% sucrose solution for cryoprotection. All
brains were sliced into 60µm serial coronal sections on a cryostat and stored in
phosphate-buffered saline (PBS)-containing well-plates for storage prior to
immunohustochemical procedures.
One series of tissue sections from each brain was selected to process PV
immunoreactivity, with sections encompassing tissue approximately -2.5mm through 6mm relative to Bregma (Paxinos & Watson, 1997) to include the septotemporal extent
of the HPC, and sections from +2.5mm through +0.25mm relative to Bregma to
encompass PFC (anterior cingulate) and caudate regions (see Figure 2.1). Free floating
sections were initially blocked in 5% normal goat serum (NGS; Jackson Immuno), 0.1%
triton-X, and PBS solution for 1 hour, followed by 3 five-minute rinses in PBS. Sections
were then transferred into primary antibody solution (1:4000 anti-rabbit parvalbumin
polyclonal antibody (Calbiochem), 0.1% triton-X, and PBS) for a 24 hour incubation
period at room temperature. Sections were then rinsed in PBS 3 times at five minutes
each, and transferred to secondary solution (horseradish peroxidase (HRP) labeled
polymer anti-rabbit; DAKO; Carpinteria, CA) for a 2 hour incubation at room
15

temperature. Following a final set of 3 five-minute rinses in PBS, sections were
transferred into a diaminobenzidine (DAB) chromogen solution (DAKO) for ten minutes
to develop the stain. Sections were mounted and dried on glass slides, then coverslipped for microscopy using DPX. Adjacent sections were processed for Nissl body
staining to assist with precise identification of brain regions.
2.3.3 Quantification of PV expression
Slides containing tissue processed for PV immunoreactivity was analyzed using a Nikon
Eclipse E600 (Melville, NY) upright microscope equipped with an Insight SPOT digital
camera (Diagnostic Instruments, Inc.). Photomicrographs of regions of interest included:
prefrontal cortex (anterior cingulate), HPC (including the CA1, CA3, and DG subdivisions), auditory cortex, caudate, retrosplenial cortex, and somatosensory barrel
fields (see Figure 2.2). For each rat, 6 photomicrographs were taken per region, with 3
representing the left hemisphere, and 3 representing the right hemisphere.
Photomicrographs for all regions were stored digitally for analysis by a researcher blind
to experimental condition. To ensure precision in the quantification of PV-expressing
cells within each region of interest, photomicrographs were taken at either 20x
magnification (CA1, CA3) or 10x magnification (cortical areas, caudate, DG).
Sections were chosen for analysis based on their anatomical location with
reference to Bregma. Prefrontal cortical (anterior cingulate) and caudate representative
sections were taken from approximately +2.5 to +0.25mm relative to Bregma (see
Figure 2.1A). Representative photomicrographs containing septal HPC, retrosplenial,
and somatosensory regions were taken from levels corresponding to -2.45mm to 3.9mm relative to Bregma (Figure 2.1B). Finally, midseptotemporal and temporal HPC
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samples were taken from levels corresponding to -5.0mm to -6.0mm relative to Bregma
(Figure 2.1C). Photomicrograph samples were analyzed using ImageJ software (NIH),
and the number of PV-immunoreactive cells was quantified using macros written to
automate particle counting within each region. An example of the ImageJ analysis can
be seen in Figure 2.3.
2.3.4 Statistical Analysis
In order to explore differences in PV-immunoreactivity within each region, the number of
PV-expressing cells, as measured using ImageJ, was averaged for each rat within each
brain region. This average was calculated using 3-6 representative photomicrographs
per region, and data was collapsed across hemispheres as there were no significant
hemispheric differences in PV expression. Two-way ANOVAs were conducted for each
HPC sub-region (CA1, CA3, DG) to determine the relationship between age (1, 6, 12
months) and septotemporal location (septal, MST, temporal). Appropriate post-hoc
analyses were conducted to explore significant main effects. Regional differences in the
average expression of PV as a function of age were assessed using one-way ANOVAs
on each region of interest (e.g. prefrontal cortex, septal CA1), followed by post-hoc
analyses where appropriate (Kirk, 2012).

2.4

Results

2.4.1 Summary of previous and current findings
In previous studies, we noted a significant decrease in PV expression across the long
axis of the HPC which varied with age (Corriveau, Master’s Thesis, 2013). We observed
a roughly 10-20% decrease in PV expression in MST and temporal regions of CA1 in 1
month old rats compared to septal regions of CA1. This septotemporal decrease along
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the HPC axis was much more prominent (over 50%) in MST and temporal – compared
to septal – CA1 in 6 month old rats. These observations were confirmed in the present
study and extended to include 12 month old rats, where there was approximately a 50%
decrease in MST and temporal CA1 compared to septal CA1. Similarly, we observed a
small decrease in PV expression along the long axis (between septal and MST regions)
within the DG, and found a significant decrease in PV expression in 6 month old rats as
compared to 1 month old rats. No obvious changes were observed in the CA3 region in
our previous work. Thus, it appears PV expression is highest in young (1 month old
Sprague-Dawley) rats with minimal septotemporal difference across the long axis of the
HPC. Age-related decreases are observed in 6 month and 12 month old SpragueDawley rats and the decline in PV expression is most prominent at more temporal
regions along the septotemporal axis.
Given the prior observations of significant changes in CA1 and the DG, our
analyses focused primarily on these two regions. In brief, the major finding of an agerelated decline in PV expression from 1 to 6 month olds was most prominent at the
temporal regions of CA1; septal and temporal regions of CA3; and both septal and MST
regions of the DG. These findings are in line with previous observations seen in our lab.
This observed decline was very similar in 12 month old compared to 1 month old rats,
with no evidence of further reductions as compared to the 6 month old group observed.
2.4.2 Cortical PV expression remains stable across lifespan
The density of PV positive neurons varied dramatically in different forebrain regions of
interest in the present study. The highest density of PV expressing cells was observed
in the somatosensory cortex (barrel fields; approximately 150 cells/1600µm²) as
compared to approximately 60-80 PV expressing cells per 1600µm² in associative
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neocortical areas (prefrontal and retrosplenial cortices). Fewer PV positive cells were
located in primary auditory cortex as well as the subcortical caudate nucleus. Despite
these regional differences, no significance changes were observed across the three age
groups. Thus, one-way ANOVA analyses revealed that there were no significant
differences in the number of PV expressing neurons within the somatosensory cortex
barrel field region (F(2, 17) = 0.44, p = 0.65) or within the prefrontal cortex (F(2, 17) =
2.32, p = 0.13) regardless of developmental age. The same pattern was seen in other
cortical regions examined, with no significant age-related changes in PV expression
within the caudate (F(2, 17) = 2.28, p = 0.14), retrosplenial cortex (F(2, 17) = 0.21, p =
0.82), or auditory cortex (F(2, 17) = 0.81, p = 0.47). Summary of findings can be seen in
Figure 2.4, and representative photomicrographs of each region across age can be
seen in Figure 2.5.
2.4.3 Septotemporal variation in HPC PV expression as a function of age
Consistent with our preliminary analysis of age and septotemporal variation in the HPC,
the density of PV positive neurons was generally less in each HPC sub-region (CA1,
CA3, DG) across all longitudinal positions (septal, MST, temporal) in 6 month old rats as
compared to 1 month old rats (see Figure 2.6). The degree of decrease was most
apparent in those areas exhibiting the highest number of PV positive neurons at 1
month of age. Two-way ANOVA analyses revealed a significant main effect of age in
CA1 (F(2,45) = 3.75, p < 0.05), CA3 (F(2,45) = 4.47, p < 0.05), and DG (F(2,30) = 9.17,
p < 0.001). A main effect of septotemporal location was also seen in HPC CA1 (F(2,45)
= 5.19, p < 0.01) and DG (F(2,30) = 12.72, p < 0.001), but not in CA3 (p > 0.10). There
were no significant interactions between age and septotemporal location in any HPC
sub-region (all p’s > 0.10).
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Post-hoc analyses conducted to explore the significant main effect of age
revealed that 1 month old rats had significantly higher PV expression than 6 and 12
month old rats in CA1(p’s < 0.05). In CA3, 1 month old rats had significantly higher PV
expression than 6 month and 12 month old rats (p > 0.01 and p = 0.05, respectively). IN
DG, 1 month old rats had significantly higher expression than 6 (p < 0.001) and 12 (p <
0.01) month old rats. PV expression in 6 and 12 month old rats did not significantly differ
from one another. See Figure 2.6 for summary of findings.
Post-hoc analyses conducted to explore the significant main effect of
septotemporal location revealed that septal CA1 had significantly higher PV expression
than temporal regions (p < 0.01), with a trend toward significance in MST (p = 0.08).
Septal CA3 had significantly more PV expression than temporal CA3 (p < 0.01), with a
trend toward significance in MST (p = 0.053). In HPC DG, septal PV expression was
significantly higher than MST regions (p < 0.001). In CA1 and CA3, there were no
significant differences between 6 and 12 month old rats (p’s > 0.10). Summary of
findings can be seen in Figure 2.7, and descriptive statistics (M±SEM) can be found in
Table 2.1.
2.4.4 HPC PV expression decreases across the lifespan
Our data revealed a significant effect of PV expression as a function of age within each
HPC sub-region (CA1, CA3, DG). One-way ANOVA analyses indicated a significant
effect of developmental age on PV expression within septal HPC regions of CA3
(F(2,17) = 4.95, p < 0.05) and DG (F(2,17) = 5.87, p =0.05). Within the MST HPC, a
significant effect of age was observed in the DG (F(2,17) = 6.82, p < 0.01). In temporal
aspects of the HPC, significant changes in PV expression as a function of age were
seen in CA1 (F(2.17) = 4.72, p < 0.05) and a trend toward significance in CA3 (F(2,17)
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= 2.96, p = 0.08). In contrast, there were no significant changes in PV expression as a
function of age in septal and MST CA1 (p’s > 0.05) or in MST or temporal CA3 (all p’s >
0.05). See Figure 2.6.
In the event that there was a main effect of age, post-hoc analyses were
conducted to explore the relationship between PV expression and developmental age.
Within CA1, LSD post-hoc analyses revealed a selective age-related change in PV
expression within temporal aspects of the region indicating that 1 month old rats had
significantly higher PV expression than 6 or 12 month old rats (p’s < 0.05). There was
no significant difference in PV expression between 6 and 12 month olds in CA1.
Septal CA3 revealed an effect of age, such that 1 month old rats had significantly
higher levels of PV-expressing cells than either 6 or 12 month old rats (p’s < 0.05), with
no difference in expression between 6 and 12 month olds. Post-hoc analysis of
temporal CA3 revealed a significant difference between 1 and 6 month old animals,
such that 1 month olds had higher PV expression than 6 month olds (p < 0.05).
Post-hoc LSD analyses within septal DG indicated a significant effect of age such
that 1 month old rats had higher PV expression than 6 month olds (p < 0.05), with a
trend toward significant between 1 and 12 month olds (p = 0.08). Within MST DG, 1
month old animals had significantly higher PV expression than 6 and 12 month old
animals (p’s ≤ 0.01); with no significant differences between 6 and 12 month old rats.
Descriptive statistics (M±SEM) for all of HPC regions can be seen in Table 2.1, and
summary of findings can be found in Figure 2.6, and representative photomicrographs
for each region can be found in Figures 2.8 – 10.
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2.5

Discussion

Our data provide support for a growing body of evidence describing an age-dependent
decline in PV expression within the HPC. The present work also provides compelling
evidence for the stable expression of PV across ages within many neocortical areas
including auditory, somatosensory, and retrosplenial cortices – at least within the age
ranges observed in the present work – which is consistent with findings across aging in
human populations (Bu et al., 2003). However, it is possible that PV expression in these
cortical regions may mature at an earlier developmental time point not included in the
current study. In contrast, there were no significant changes across neocortical tissue
and no age-related changes in PV expression within the striatum across groups,
consistent with previous findings indicating stability in PV expression as a function of
age in the caudate region (Bae et al., 2015). The present data from the medial
prefrontal cortical area (specifically the anterior cingulate cortex) revealed a trend
toward statistical significance such that as age increased, as did the relative density of
PV expression (see Figure 2.5). This finding mirrors human data suggesting an increase
in PV expression commiserate with age (e.g., Fung et al., 2010; Reynolds & Beasley,
2001), which likely underlies normal age-dependent maturation of prefrontal inhibitory
circuitry (Lewis et al., 2006). In summary, it appears that dynamic changes in PV
expression may mirror the delayed development of higher-order associative cortices
including the HPC and prefrontal cortical areas (CITE).
The most prominent changes were evidenced within the HPC, where we
observed a significant decline in PV expression as a result of age in CA1, CA3, and DG
regions. 1 month old rats generally express higher levels of PV immunoreactivity than 6
and 12 month old rats, suggesting that expression may be developmentally dynamic.
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These findings are in agreement with previous studies reporting age-related decreases
in PV expression within the HPC (Lee et al., 2013; Shetty & Turner, 1998; de Jong et
al., 1996; Lolova & Davidoff, 1992), though these findings are primarily in reference to
septal regions. Importantly, our data argues against findings indicating an absence of
age-related decline (e.g. Hwang et al., 2008; Potier et al., 2006; Vela et al., 2003;
Kishimoto et al., 1998; Miettinen et al., 1993) or the presence of age-related increases
(e.g., Choi et al., 2010) in HPC PV expression.
Findings from Nomura and colleagues (1997) indicate a high degree of PV
expression within young (5 week old) rats that is in line with our findings of high levels of
PV expression coinciding with a lack of HPC septotemporal PV gradient in 1 month old
rats. In the current study, we found that there were notable septotemporal variations in
PV immunoreactivity within the HPC formation in 6 and 12 month old rats. Specifically,
we observed a significant decrease in PV expression from septal to MST and temporal
CA1, with no difference in expression between MST and temporal CA1 locations in 6
and 12 month old rats. This pattern of HPC septotemporal gradient in PV expression
was selective to CA1 regions, with CA3 regions showing consistent PV expression
across the long axis in both 6 and 12 month old rats. However, it is worth noting that the
DG region of the HPC trends toward a statistically significant septotemporal gradient
from septal to MST regions in both 6 and 12 month old rats – a finding which is in
agreement with previous investigations (Corriveau, Master’s Thesis, 2013).
The lack of septotemporal difference within the CA3 region in all age groups
might suggest the possibility that PV expressing neurons in this region may be more
resilient to the effects of aging, however previous work looking at age-related effects of
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calcium dysregulation suggest that all HPC sub-regions are negatively impacted by
aging (Mattson & Magnus, 2006). CA1 and DG regions may exhibit increased
vulnerability to the adverse effects of aging, as evidenced in cognitive-behavioral tasks
and imaging studies (e.g., Small et al., 2004; Barnes et al., 1997; for review see Burke
& Barnes, 2006). Overall, these findings indicate a dynamic interaction between aging,
HPC sub-region (CA1, CA3, DG), and septotemporal location within the HPC on overall
immunohustochemical visualization of the calcium-binding protein PV. The present
study is the first to systematically characterize the expression of PV immunoreactivity
across the septotemporal axis of the HPC within three distinct developmental time
points.

2.6

Conclusion

Overall, we present compelling evidence in support of age-dependent decreases in PV
protein expression within CA1, CA3 and DG regions of the HPC from 1- to 6-month old
rats, a finding which is sustained for minimally up to 12 months old age. A decrease in
PV expression across the septotemporal extent of the HPC was evident in the CA1
regions of 6 and 12 month old rats, with preservation of PV levels across the long axis
in all regions within 1 month old rats. Evidence for a dynamic interaction between PV
protein expression within the HPC and neocortical and striatal regions as a function of
developmental age suggest that PV expression is differentially regulated depending on
brain location. The present findings provide a normative developmental framework to
inform future studies looking at both normal and pathological distribution of PV protein
expression in rodents. Specifically, the regional and age-related differences presently
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shown here can shape future experiments seeking to understand the acute and longterm impact of pharmaceutical agents (e.g. NMDA-antagonists) and their relationship to
PV-related neuropathology.
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Figure 2.1: Location of representative sections relative to Bregma (ß)
Sections processed for PV immunoreactivity were selected for analysis of PV expression across
the long axis of the HPC, as well as within the prefrontal cortex (anterior cingulate), caudate,
somatosensory barrel fields, and retrosplenial cortex. Anterior cingulate and caudate samples
were taken from sections between +2.5mm and +0.5mm relative to Bregma (A). Septal HPC
regions (CA1, CA3, DG), somatosensory barrel fields, and retrosplenial cortex samples were
taken from sections between -2.45mm and -3.9mm relative to Bregma (B). Midseptotemporal
(CA1, CA3, DG) and temporal (CA1, CA3) HPC samples were taken from sections between 5.0mm and -6.0mm relative to Bregma (C). This figure serves as an example of how each brain
was processed; note that photomicrographs were taken in both hemispheres of the sampled
sections, and that sections were roughly 240µm apart from one another.
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Figure 2.2: Anatomical locations of photomicrographs samples taken for PV analysis in
hippocampal and cortical regions of interest.
Photomicrographs of frontal cortical (anterior cingulate cortex) (A.1) and caudate (A.2) were
sampled between +2.5 through +0.25mm relative to Bregma. Retrosplenial cortex (B.1),
somatosensory barrel fields (B.2), and septal regions of HPC – including DG (B.3), CA1 (B.4),
and CA3 (B.5) – were sampled between -2.45 through -3.9mm relative to Bregma.
Midseptotemporal DG (C.1), CA1 (C.2), and CA3 (C.3) – as well as temporal CA1 (C.4) and
CA3 (C.5) – were sampled between -5.0 through -6.0mm relative to Bregma. All cortical regions,
as well as all DG regions, were photographed at a magnification of 10x, while all CA1 and CA3
regions were photographed at a magnification of 20x. Photomicrographs of analyzed samples
were taken within the boxed regions of interest as outlined in the figure.
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Figure 2.3: Example of quantification of PV-expressing cells using ImageJ Color-Based
Thresholding.
ImageJ software was used to automize PV+ cell counting using region- and magnificationspecific macros to ensure unbiased, consistent quantification within each area of interest.
Examples of threshold-based quantification from septal HPC CA1 (A) and somatosensory barrel
fields (B) can be seen above. The left set of panels show original photomicrographs with darkly
stained PV+ cells clearly evident. The center panel shows the same photomicrograph
thresholded based on color density to isolate the most darkly stained cells. A macro was run to
quantify the number of PV+ cells based on previously set parameters to exclude any
thresholded particles (e.g. non-cell artifacts) which did not meet criteria for inclusion (e.g. size,
sphericity). The right panel shows the output from the macro identifying counted PV+ cells.
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Figure 2.4: Parvalbumin expression remains stable across the lifespan within the
neocortex and striatum.
Analysis of PV expressing neurons within the neocortex and striatum revealed no significant
changes in expression between 1, 6, and 12 month old rats within neocortical areas (auditory,
frontal (anterior cingulate), retrosplenial, and somatosensory cortices), or the striatum (caudate).
All p’s > 0.05.
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Figure 2.5: PV expression as a function of age and brain region in the neocortex and
striatum
Representative photomicrographs of neocortical and striatal regions of interest included (from
top of figure to bottom): rat auditory cortex, caudate, prefrontal cortex (anterior cingulate region),
retrosplenial cortex, and somatosensory cortex (barrel fields). There were no significant
changes observed in PV expression within these regions. However, there was a trend toward
significance in the prefrontal cortex suggesting that PV expression may increase as a function of
age. Photomicrographs were taken at 10x magnification.

31

Figure 2.6: Age-dependent changes in PV expression as a function of hippocampal
region and septotemporal location.
There were significant differences in all HPC sub-regions (CA1, CA3, DG) as a function of age,
such that there was a general pattern of more PV expressing cells in 1 month old rats compared
to 6 and 12 month old rats. Specifically, in the temporal region of CA1 (A), 1 month old rats had
significantly higher PV expression than both 6 and 12 month old rats. In CA3 (B), 1 month old
rats had significantly higher PV expression in septal regions than 6 and 12 month olds; and 1
month olds had significantly higher PV expression than 6 month olds in temporal CA3. Within
the DG (C), 1 month old rats had significantly higher PV expression than 6 month olds in septal
regions, and significantly higher than 6 and 12 month olds in midseptotemporal regions.
*p < 0.05, **p < 0.01
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Figure 2.7: PV expression varies across the septotemporal axis in CA1 in 6 and 12 month
old rats.
No significant changes in PV expression were seen across the septotemporal axis of the HPC in
1 month old rats (A) in any of the HPC sub-regions (CA1, CA3, DG). In 6 month old rats (B),
there was a significant decline in PV expression from septal to MST and temporal areas, with no
significant changes across the long axis in CA3 or DG. Similarly, 12 month old rats (C) had
significantly higher PV expression in septal compared to temporal CA1, with no significant
differences across the long axis in CA3 or DG.
*p < 0.05

33

Figure 2.8: PV expression in HPC CA1 as a function of age and septotemporal location
Representative photomicrographs visualizing PV expression in CA1 as a function of
developmental age (1, 6, 12 months) and septotemporal location (septal, midseptotemporal
(MST), and temporal). PV expression remained stable across ages in septal and MST regions,
but was significantly reduced in 6 and 12 month old rats compared to 1 month old rats in
temporal regions. In 1 month old rats there was no effect of septotemporal location on PV
expression, whereas 6 and 12 month old rats had significant decreases in expression along the
septotemporal axis from septal to temporal regions. Photomicrographs were taken at 20x
magnification.
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Figure 2.9: PV expression in HPC CA3 as a function of age and septotemporal location
Representative photomicrographs visualizing PV expression in CA3 as a function of
developmental age (1, 6, 12 months) and septotemporal location (septal, midseptotemporal
(MST), and temporal). PV expression remained stable across ages in MST regions, but was
markedly reduced in 6 and 12 month old rats compared to 1 month old rats in septal and
temporal regions. There were no significant changes in PV expression across the septotemporal
axis in this region. Photomicrographs were taken at 20x magnification.
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Figure 2.10: PV expression in HPC DG as a function of age and septotemporal location
Representative photomicrographs visualizing PV expression in DG as a function of
developmental age (1, 6, 12 months) and septotemporal location (septal and midseptotemporal
(MST)). The pattern of PV expression shows a general decrease across the septotemporal axis,
with less expression within the MST as compared to septal regions. 1 month old rats generally
had higher PV expression within the DG than both 6 and 12 month old rats. Photomicrographs
were taken at 10x magnification.
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Table 2.1: Descriptive Data

Auditory
Caudate
Prefrontal (Cingulate)
Retrosplenial
Somatosensory

1 Month

6 Months

12 Months

34.5 ± 6.0
7.8 ± 1.6
38.6 ± 7.1
75.6 ± 15.0
156.4 ± 30.7

37.3 ± 7.7
10.4 ± 1.4
61.9 ± 9.4
67.8 ± 9.4
128.8 ± 12.7

58.7 ± 23.6
14.1 ± 2.9
69.0 ± 13.7
65.9 ± 8.1
147.3 ± 15.5

Hippocampus
CA1

Septal
MST
Temporal

15.1 ± 3.4
12.8 ± 3.1
11.9 ± 1.8

12.8 ± 2.0
7.1 ± 1.5
5.6 ± 2.0*

12.6 ± 1.5
10.8 ± 2.7
5.3 ± 1.3*

CA3

Septal
MST
Temporal

12.4 ± 2.2
6.7 ± 2.4
11.9 ± 1.9

5.5 ± 1.2*
6.0 ± 1.0
7.1 ± 1.1*

5.2 ± 1.9*
7.5 ± 2.0
9.9 ± 1.1

DG

Septal
MST

5.8 ± 1.2
3.7 ± 0.6

2.8 ± 0.6*
1.0 ± 0.2*

3.6 ± 0.4
1.3 ± 0.7*

Descriptive data in the above table is expressed as M ± S.E.M. and represents the average
number of PV expressing cells per 1600µm² for each region (n’s = 6).
Within the HPC, an asterisk (*) following the M±SEM indicates that the PV expression is
significantly different from 1 month old rats at the p < 0.05 level
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CHAPTER 3
Chronic ketamine administration impairs cognitive performance in a DMTS water
maze task without concomitant changes in parvalbumin expression

3.1

Abstract

A selective decrease in parvalbumin (PV) immunoreactivity is a robust finding in
postmortem schizophrenic hippocampus (HPC) and prefrontal cortex. Rodent models of
schizophreniform cognitive dysfunction following acute and/or chronic ketamine (KET)
treatments show comparable decreases in PV expression, and it is often considered a
maker of neuropathology. However, the literature detailing KET-induced cognitivebehavioral impairment reveals inconsistent – and often contradictory – findings with
regard to concomitant changes in PV expression within key brain regions implicated in
cognition. In order to provide clarity to this growing body of literature, the present study
sought to explore the short- and long-term impact of chronic KET administration
(30mg/kg for 14 consecutive days) compared to saline controls on cognitive
performance in a delayed matching-to-sample radial water maze task. Additionally, the
present work sought to elucidate upon the relationship between chronic KET-induced
cognitive impairment and levels of PV immunoreactivity within the HPC,
prefrontal/cingulate cortex, and retrosplenial cortex of adult male Sprague-Dawley rats.
Our data suggests that, while chronic administration of KET does, indeed, impair
cognitive performance in a spatial navigation task, it does not significantly alter PV
immunoreactivity within any of the brain regions observed. These findings indicate that
chronic KET-induced cognitive impairment may be occurring independently of PV
expression within inhibitory GABAergic neurons in these regions. Furthermore, these
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findings provide compelling evidence that PV immunoreactivity may not be the
underlying neural mechanism of KET-induced cognitive impairments, and therefore may
not be a suitable marker of schizophreniform pathology.
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3.2

Introduction
Schizophrenia (SCZ) is a complex psychological disorder characterized by

marked impairments in prefrontal and medial temporal lobe supported cognitive
processes (Eisenberg & Berman, 2010). The exact etiology of these impairments
remain unclear, however it is thought that NMDA receptor hypofunction , in addition to
downstream consequences, may underlie impairments in cognitive functioning
(Anticevic et al., 2012; Moghaddam & Javitt, 2012; Snyder & Gao, 2013).
A number of investigators have used acute and chronic treatment with the NMDA
antagonist, ketamine (KET), to induce cognitive, behavioral, and neuropathological
features of SCZ (Frohlich & Van Horn, 2014; Steeds et al., 2015). Within the human
literature, there is evidence for acute KET-induced disturbances in memory and
executive function comparable to those seen in SCZ patients (e.g. Parwani et al., 2005;
Honey et al., 2006; Lofwall et al., 2006). A review of the literature by Morgan and Curran
(2006) suggests that acute administration in humans significantly impairs working
memory performance, while chronic use may create long-lasting KET-independent
impairments in the formation of episodic memories (Curran & Monaghan, 2001).
Furthermore, chronic KET use in humans is correlated with deficits in prefrontal and
medial temporal lobe driven cognitive processes such as visual recognition memory
(Chan et al., 2013) and spatial working memory (Morgan et al., 2010), which mirrors
dysfunction seen in patient populations.. Comparable to the human literature,
administration of acute and/or chronic sub-anesthetic doses of KET have been shown to
produce significant impairments in working and reference memory (Enomoto &
Floresco, 2009; Rushforth et al., 2011), episodic-like spatial memory (Chrobak et al.,
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2008), and spatial alternation (Verma & Moghaddam, 1996), as evidenced in behavioral
tasks.
Postmortem findings point to a selective decrease in the calcium-binding protein
(CBP), parvalbumin (PV), within prefrontal cortical (Beasley & Reynolds, 1997) and
hippocampal (HPC; Zhang & Reynolds, 2002) GABAergic inhibitory neurons. Acute and
chronic KET administration has been shown to produce pathological changes in the
expression and distribution of the PV within neural circuits in key brain regions such as
the prefrontal cortex and HPC (e.g., Keilhoff et al., 2004; Behrens et al., 2007;
Kittelberger et al., 2012; Zhou et al., 2015). However, there exists conflicting findings
suggesting the possibility that KET administration may actually serve to increase PV
expression (e.g. Sabbagh et al., 2013), or that it may have no discernable impact on
levels of PV immunoreactivity (e.g. Benneyworth et al., 2011). Overall, the literature to
date on this phenomenon is limited and is in need of further characterization to clarify
the relationship between chronic NMDA antagonism, cognitive-behavioral performance,
and concomitant changes in PV immunoreactivity.
In order to characterize the relationship between these variables, the goals of the
current study were two-fold, and aimed to investigate: 1) the acute and long-term impact
of chronic KET administration on performance in a delayed matching-to-sample radial
water maze task (DMTS-RWM); and 2) the effect of chronic KET treatment on
neuropathology, with specific emphasis on PV immunoreactivity within the HPC and
prefrontal cortex. Our findings suggest that there may not be a clear relationship
between cognitive dysfunction in a DMTS-RWM cognitive-behavioral task and PV
expression as a result of chronic KET exposure in adult rats.
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3.3

Methods

3.3.1 Subjects
Twenty adult (approximate age1- 6 months during behavioral training) male Sprague
Dawley rats (Charles River Laboratories, Wilmington, MA) were used in the current
study. All rats were individually housed in clear polycarbonate caging with free access
to food and water until rats weighed ~450 grams, At ~4 months of age eat rat received
approximately 20-24 grams of rat chow per fay with free access to water. Normal
husbandry procedures were followed for all rats in a temperature and humidity
controlled vivarium with a 12-hour light/dark cycle (lights on at 0800h). Rats were
behaviorally trained in a DMTS-RWM task (see Chrobak et al., 2008 for detailed
methods) beginning at approximately 1 month of age and continued until rats were
sacrificed and their brain tissue was collected (approximately 6-7 months of age). At
approximately 6 months of age, when rats were well-trained on the maze task, half of
the rats received a chronic regimen of either KET (30 mg/kg IP; n = 10) or a comparable
intraperitoneal (IP) injection of physiological saline (n = 10). All housing and
experimental procedures were performed in accordance with, and approved by, the
University of Connecticut Institutional Animal Care and Use Committee.
3.3.2 Behavioral testing – delayed matching to sample radial water maze task
Rats were trained and d tested in the delayed matching-to-sample radial water maze
(DMTS-RWM) cognitive-behavioral task to assess the impact of chronic KET
administration on cognitive performance. The delayed matching-to-sample radial water
maze task (DMS-RWM) is comprised of a 140cm diameter black fiberglass pool with a
depth of 40cm. The pool houses eight black removable stainless steel corridors
measuring 14cm wide x 36cm long and they extend from a central octagonal hub
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measuring 50cm in diameter. The pool is filled with cool water (22 ± 2ºC) with the
corridor walls extending 16cm above water level. A removable 10cm in diameter black
PVC platform is submerged approximately 6cm below the surface of the water which
serves as a hidden escape route from the pool.
Shortly following arrival into the colony rats were given four days of standard
Morris water maze (four trials per day from each of four start locations to a fixed goal
position; beginning at approximately 1 month of age) training to acclimate them to water
escape and the general testing procedure. On the fifth day, the goal location was moved
to a different location to test their reversal performance over four trials on that day. The
following week, rats were trained on a delayed matching-to-sample radial water maze
(DMTS-RWM) task with control trials and standard protocols implemented as outlined
previously (Chrobak et al.., 2008). Briefly, rats were initially trained with a single ‘forcedchoice’ sample session followed by a single thirty minute delayed test trial each day for
eight weeks. Subsequently, rats were trained on a series of delay trials during which the
sample-test interval were systematically varied between 5 minutes to 8 hours. After the
completion of delay trial testing (~6 weeks), rats were tested on a series of two sampletest trials each day where the interval between each sample-test and the interval
between sample-test sessions were systematically varied to examine the degree of
interference exhibited across the two sample-test sessions within a day (see Figure 3.1
for example).
After five months of training and testing with either a single, or two, sample-test
trials each day rats were tested with a fixed series of two sample-test trials as indicated
in Figure 3.1. Morning trials consisted of a forced sample, followed by a 30 minute
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delayed test (see Figure 3.1A), while afternoon trials consisted of a forced sample,
followed by a 30 minute delayed second sample, and then a 5 minute delayed test trial
(see Figure 3.1B). Rats were tested in this manner for 8 days prior to KET treatment
(see Figure 3.2) as well as throughout the duration of chronic KET treatment (14
consecutive days) and were additionally tested for 10 days subsequent to the 14-day
KET regimen. Importantly, KET treatments were administered between 4-6pm each
evening approximately 2 hours after the completion of the behavioral training. Thus,
none of the behavioral data was collected with KET “on-board” but minimally 12-14
hours post KET treatment.
3.3.3 Drug administration
Following extensive behavioral training in the DMS-RWM, rats began a chronic KET
treatment regimen to induce hypoactivation of NMDA receptors within the brain. Rats
were randomly assigned to one of two experimental groups consisting of either 1)
chronic KET (n = 10) or 2) comparable saline (n = 10). Rats in the chronic KET group
received a 30 mg/kg dose delivered IP once per day, while the control group received a
comparable IP injection of physiological saline for 14 consecutive days. Injections were
given at the same time each day (between 4-6pm) for the duration of the treatment, and
were administered subsequent to any of the DMTS-RWM testing, ensuring that the
treatment would not interfere with task performance. To explore any long-term impact of
KET treatment on cognitive performance, we continued to test rats 10 days post drugcessation, after which rats were perfused and brain tissue collected.
3.3.4 Immunohistochemistry
Rats were anesthetized with Euthasol (pentobarbital sodium solution; 1mL via IP
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injection) and transcardially perfused with ice-cold 0.9% physiological saline solution
immediately followed by ice-cold 3.7% paraformaldehyde solution. Following perfusions,
brains were removed and individually stored in scintillation vials filled with 3.7%
paraformaldehyde solution for 1 week. Prior to sectioning, brains were transferred into a
30% sucrose solution for cryoprotection. Brains were sliced into 60µm serial coronal
sections on a cryostat and were stored in phosphate-buffered saline (PBS)-containing
well-plates for storage prior to immunohustochemical procedures.
One series of tissue sections from each brain was selected to examine PV
immunoreactivity, with sections encompassing tissue approximately -2.5mm through 6mm relative to Bregma (Paxinos & Watson, 1997) to include the septotemporal extent
of the HPC, as well as retrosplenial and somatosensory cortices. Additionally, sections
encompassing tissue ranging from approximately +2.5mm through +0.25mm relative to
Bregma were collected to examine PV expression within the anterior cingulate cortex.
Refer to Figure 2.1 for section selection specifications. Free floating sections were
initially blocked in 5% normal goat serum (NGS; Jackson Immuno), 0.1% triton-X and
PBS solution for 1 hour, followed by 3 five-minute rinses in PBS. Sections were then
transferred into primary antibody solution (1:16000 anti-rabbit PV polyclonal antibody
(ABCAM), 0.1% triton-X, and PBS) for a 1 hour incubation period at room temperature.
Sections were then rinsed in PBS 3 times and transferred to secondary solution
(horseradish peroxidase (HRP) labeled polymer anti-rabbit; DAKO) for a 1 hour
incubation at room temperature. Following a final set of rinses in PBS, sections were
transferred into a diaminobenzidine (DAB) chromogen solution (DAKO) for ten minutes
to develop the stain. Sections were mounted and dried on glass slides, then cover-

45

slipped for microscopy using DPX.
3.3.5 Quantification of PV expression
Glass microscopy slides containing tissue processed for PV immunoreactivity was
analyzed using a Nikon Eclipse E600 (Melville, NY) upright microscope equipped with
an Insight SPOT digital camera (Diagnostic Instruments, Inc.). Photomicrographs of
regions of interest included: anterior cingulate cortex, HPC (including the CA1, CA3,
and DG sub-divisions; as sampled in Stuellet et al., 2010 and Nomura et al., 1997),
retrosplenial cortex, and barrel field cortex were compiled and stored digitally for
analysis by a researcher blind to treatment condition. To ensure precision in the
quantification of PV-expressing cells within each region of interest, photomicrographs
were taken at either 20x magnification (CA1, CA3) or 10x magnification (cortical areas;
DG). Refer to Figure 2.2 for photomicrograph sampling locations for each region of
interest.
Digital photographs were analyzed using ImageJ software (NIH), and the number
of PV-immunoreactive cells quantified using macros written to automate particle
counting within each region of interest (for an example of color-thresholding analysis
using ImageJ software, refer to Figure 2.3). The sizes of the analyzed regions were as
follows: CA1/CA3, 800µm²; DG and cortical areas, 1600µm². HPC CA1 and CA3
averages were normalized to represent the average number of PV reactive cells per
1600µm² for cross regional comparisons and consistency across data sets.
3.3.6 Statistical Analysis
3.3.6.1

Analysis of DMTS-RWM performance

Performance measures for the DMTS-RWM task include: 1) mean number of errors (the
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number of incorrect corridor entries during test trials); 2) latency per choice (total time to
navigate to the goal corridor divided by the number of choices made); and 3) first choice
latency (time to navigate to the first corridor during the test trial, regardless of choice).
For the purpose of the current analyses, only mean error during test trials is presented.
In order to determine whether chronic KET administration significantly impaired
cognition in the DMTS-RWM task compared to saline-treated controls, split-plot two-way
repeated measures analyses of variance (RMANOVAs; Wickens & Keppel, 1983; Kirk,
1982) for treatment, trials (analyzed in 2 day blocks), and treatment by day interactions.
Separate RMANOVA’s were conducted on performance 1) during 4 x 2-day blocks (8
days) prior to treatment (pretreatment), 2) during7 x 2-day blocks (14 days) during KET
treatment, and 3) during3 x 2-day blocks (6 days) subsequent treatment (posttreatment; to determine the effect of treatment on mean errors following KET). Where
appropriate, significant RMANOVA’s were followed up with Tukey’s HSD post-hoc
analyses (Kirk, 1982) to compare differences between saline controls and KET
treatment on specific 2-day blocks.
3.3.6.2

Analysis of PV expression

In order to explore differences in PV-immunoreactivity within each region, the number of
PV-expressing cells within each brain region, as measured using ImageJ, was averaged
for each rat and then group means were computed for each age. The average for each
brain region was calculated using 3-6 representative photomicrographs per region (2-3
photomicrographs for each hemisphere), and was collapsed across hemispheres as
there were no significant differences in PV expression observed. This was done to
determine whether there were differences across HPC regions (CA1, CA3, DG) at all
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septotemporal locations (septal, MST, temporal), in addition to possible differences
within/across neocortical areas as a result of KET treatment. Averages for each HPC
region were calculated such that each rat contributed data points for each region at
each septotemporal location. Differences in the distribution of PV expression as a
function of KET treatment within all regions of interest (e.g. anterior cingulate; CA1)
were assessed using one-way Analysis of Variance (ANOVA), followed by post-hoc
analyses where appropriate (Kirk, 2012).

3.4

Results

3.4.1 DMTS-RWM performance is impaired by chronic KET treatment
Consistent with prior preliminary data in a 24 month old group of well-trained rats, we
observed no impairment in performance following repeated KET administration during
performance of a single daily sample-test session. In this case, the delay interval was
30 minutes and both groups of rats exhibited fairly stable performance (approximately,
0.2-1.0 mean errors per day and 2-day block for both groups) with roughly 50% of rats
making no errors, and the remaining making 1-2 errors per day on any given day of
testing. It should be noted that such performance is typical across delay intervals from 1
minute to several hours (see Chrobak et al., 2008). RMANOVA’s for each block of
testing (pretreatment, KET treatment, and post-treatment) indicated no significant effect
of treatment, day, or treatment by day interactions (see Figure 3.2A; p’s > 0.4).
In contrast, well-trained 6 month old rats exhibited marked memory deficits by
day 7-8 of KET treatment on the “high” interference trials of the afternoon session (see
Figure 3.2B). Notably, this group of rats was well trained to perform the DMTS-RWM
task with one, two, or three forced sample-test pairs within the same day. It should also
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be noted, that we do not typically test rats on multiple sample-test pairs each day for
many days; rather, such multiple same-test pairs are parsed between single sample-test
pairs (e.g., every other or third day) as performance during such high interference trials
improves over consecutive daily testing trials.
Performance in both groups was similar during the pretreatment blocks (see
Figure 3.2A; p’s > 0.5) with both groups making 0.9-1.5 errors per day (or 2-day blocks).
Notably, KET treated rats began exhibiting progressively impaired performance as
compared to controls by day 7-8 of testing through the last 13-14 days of testing. A
RMANOVA during the KET treatment period indicated a significant trial by treatment
effect (F(1,9) = 11.4, p < 0.01), a significant trial effect (F(6,54) = 8.22, p < 0.01), and a
significant treatment interaction (F(6,54) = 5.44, p < 0.01). Post-hoc analyses indicated
significant differences during the 7-8 day block and all subsequent testing during the
treatment period.
Upon the cessation of treatment, KET treated rats did not exhibit a sustained
impairment; rather, performance improved to control levels by day 3-4 post-treatment. A
RMANOVA on the post-treatment period indicated a significant difference (p < 0.01) on
only the first 2 days (48 and 72 hours) post KET treatment.
3.4.2 No effect of chronic KET treatment on PV expression within the cortex
Within the cortical regions of interest, one-way ANOVA analyses revealed that there
were no significant differences in the average number of PV immunoreactive neurons
as a function of treatment. There was no significant effect of chronic KET administration
as compared to saline controls within the anterior cingulate cortex (F(1,19) = 1.53, p =
0.23), the retrosplenial cortex (F(1,19) = 1.35, p = 0.26), or within the somatosensory
barrel fields (F(1,19) = 0.12, p = 0.73). A summary of findings can be seen in Figure 3.3,
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with representative photomicrographs of these regions in Figure 3.4. Descriptive
summarization of data can be seen in Table 3.1.
3.4.3 No effect of chronic KET treatment on PV expression within the HPC
Overall, there were no significant effects of chronic KET administration on average
levels of PV immunoreactivity within the HPC. This lack of significance was seen in CA1
(F(1,59) = 1.05, p = 0.31), CA3 (F(1,59) = 0.29, p = 0.59), and DG (F(1,39) = 0.75, p =
0.39).Summary of data can be seen in Figure 3.5. These findings indicate that chronic
KET administration did not concomitantly alter PV immunoreactivity in these HPC
regions as compared to saline-treated controls. Representative photomicrographs of
these regions at all septotemporal locations can be seen in Figure 3.6.

3.5

Discussion

The present findings provide support to a small body of research indicating no change
in PV immunoreactivity following chronic KET administration in adult rats. Our data is in
agreement with previous work by Benneyworth and colleagues (2011) which indicates
no effect of repeated KET treatment on PV immunoreactivity in mice or rats.
Furthermore, they report no change in the HPC or prefrontal cortex as a result of
chronic KET treatment, which is in line with the present findings. A growing number of
groups utilizing other non-competitive NMDA antagonist drugs (e.g. MK-801 or PCP)
have also reported the absence of chronic NMDA hypofunction-induced changes in PV
immunoreactivity in these brain regions (e.g., Braun et al., 2007), though the aggregate
impact of these findings is underwhelming when compared to the number of published
studies indicating clear decreases in PV expression following similar pharmacological
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treatments (e.g. Keilhoff et al., 2004; Kittelberger et al., 2012; for review see JaaroPeled et al., 2010).
Alternatively, it is possible that the absence of KET-induced changes in PV
immunoreactivity may be due to the behavioral and/or cognitive training that the rats in
the current study experienced. Our lab has previously observed marked up-regulation in
PV immunoreactivity in 24 month old rats that had undergone extensive behavioral
training in the DMTS-RWM task for approximately 1.5 years. Interestingly, this increase
in expression was seen within all observed brain regions (e.g. neocortex; HPC) when
compared to younger, behaviorally-naïve rats (Corriveau, Master’s Thesis, 2013).
Previous research has linked environmental enrichment to increases in PV
immunoreactivity (e.g., Iuvone et al., 1996; Urakawa et al., 2013). Komitova and
colleagues (2013) found that environmental enrichment was able to attenuate hypoxiainduced PV-expression abnormalities. This ‘rescue’ effect of PV phenotype driven by
enrichment may explain the lack of significant changes in PV expression following
chronic KET administration, as the sustained behavioral training impacts the system in a
similar, albeit perhaps more robust, manner as environmental enrichment. Other labs
have reported comparable results, with behavioral experience and/or cognitive training
recovering insult-induced loss of PV reactivity in the rodent brain (e.g. de Villers-Sidani
et al., 2010; Zhou et al., 2015).
In the present study, we describe chronic KET-induced deficits in DMTS-RWM
performance when compared to saline-treated controls. However, due to a lack of effect
of KET treatment on PV expression, it is difficult to determine whether observed
cognitive-behavioral deficits were driven by impairment in the PV-expressing
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GABAergic inhibitory circuitry. The absence of a relationship between these two factors
could be explained by: 1) a KET-induced cognitive impairment which is independent of
aberrations in PV immunoreactivity; 2) the sustained cognitive-behavioral training before
and during chronic KET treatment, thereby buffering the deleterious impact of KET on
overall PV expression; or 3) the timeline of tissue collection for PV
immunohustochemical examination. As PV has been inextricably linked to the
coordination of neuronal ensembles integral for sustained and efficient cognitive
processes, it is unlikely that the impairments described herein are not driven, in some
way, by KET-induced dysfunction in PV function (Carlen et al., 2012; Gonzalez-Burgos
et al., 2015). This disconnect is more likely influenced by the behavioral training and/or
the delay between KET treatment-cessation in tissue collection. Since brain tissue was
collected 10 days post-cessation, it is possible that this delay may have provided ample
time for PV immunoreactivity to normalize. Behrens and colleagues (2008) show a twofold increase in PV expression 10 days post KET cessation when compared to 1 day
post-cessation, indicating a recovery of PV phenotype. This argument becomes
stronger when the recovery of cognition comparable to control performance in the
DMTS-RWM task is seen 2-3 days following the end of the chronic KET regimen, and
could therefore be indicative of a concomitant recovery of both cognitive performance
and PV phenotype.

3.6

Conclusion

Overall, the present study provides compelling evidence for schizophrenic-like cognitive
impairment in a DMTS-RWM task in rats chronically treated with KET as compared to
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controls. Furthermore, we provide evidence for a prolonged effect of chronic KET
exposure on cognitive dysfunction, which eventually returns to baseline control
performance 2-4 days post-cessation. An effect of treatment on PV immunoreactivity
within the neocortex and HPC was not observed, and is likely a consequence of the
cognitive-behavioral training mediating the deleterious effects of the KET regimen, or a
time-dependent recovery of PV phenotype following cessation; or perhaps some
combination of the two. These findings suggest the possibility that cognitive-behavioral
experience/training may serve to buffer the anatomical effects imposed by chronic KET
administration, which provides support for behavioral therapies in mediating cognitive
deficits in schizophrenic patient populations. We propose that additional studies be
conducted to conclude whether behavioral training and/or timeline of tissue collection
significantly impact PV immunoreactivity following chronic KET protocols.
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Figure 3.1: Delayed matching-to-sample radial water maze (DMTS-RWM) trial procedure
Beginning 1 week pre-treatment, rats were given two trial sessions per day consisting of AM
trials (A) and PM trials (B). AM trials consisted of an initial forced sample, where rats were
started at a randomized start (“S”) location with all corridors except the goal (“G”) blocked. Rats
were then given a 30 minute retention interval before being placed back in the pool at a new
start location and all corridors open to determine whether the rat remembered the most recent
goal location. During PM trials (B), rats were placed in a random start (“S”) location with all
corridors but the goal (“G”) blocked, then given a 30 minute retention interval. Rats were then
returned to the pool for a second forced sample trail, with the goal in a new location, and upon
locating the new goal location, were given a 5 minute retention interval. Rats were returned to
the pool from a new start location with all corridors open for a test trial in order to determine
whether rats could locate the most recent goal representation. If rats remembered the most
recent goal location, they showed no impairment. However, if rats went to either the first forced
sample goal location from the PM trials, or the goal location from the AM trials, it was
considered an error imposed by proactive interference from a previous, and now incorrect, goal
representation.
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Figure 3.2: KET significantly impairs DMTS-RWM performance compared to Saline
DMTS-RWM training took place twice per day and included: AM trials (A) and PM trials (B). In
the AM trials (A), rats received a forced sample trial (FS) to learn the location of a hidden
platform goal (indicated by “G”) from a randomized start (indicated by “S”) location. The FS was
followed by a 30 minute retention interval, after which the rats were returned to the pool to a
new start location to find the previously learned goal. In the PM trials (B), rats were given a FS,
followed by a 30 minute retention interval, then a second FS with a new goal location. This new
FS trial was followed by a 5 minute retention interval, after which the rats were returned to the
pool to a new start location. In order to make a correct first choice and escape the pool, rats had
to go to the most recent goal location (as indicated during FS). During AM trials, chronic KET
treatment did not impact pre-treatment (PRE), during treatment (KET Treatment), or posttreatment (POST) cognitive performance (A). However, during the proactive interference trials in
the PM trials, chronically KET treated rats had significantly more errors that saline control during
KET treatment beginning at day 8 and continuing 2 days post-treatment (B). There was no
effect of KET during PRE trials or during POST trials (after 4 days post-KET).
*p < 0.05

*p < 0.01
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Figure 3.3 Chronic KET administration does not alter cortical PV expression
Chronic KET administration (30mg/kg KET for 14 consecutive days) in adult male rats did not
impact overall PV expression within the prefrontal (cingulate) cortex, retrosplenial cortex, or
somatosensory (barrel field) cortex compare to saline-treated controls.
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Figure 3.4 Representative photomicrographs: Cortex
Representative photomicrographs taken from prefrontal (cingulate) cortex, retrosplenial cortex,
and somatosensory barrel fields. As can be seen, chronic KET administration did not alter
overall PV immunoreactivity as seen in saline controls.
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Figure 3.5 Chronic KET administration did not alter hippocampal PV expression
Chronic NMDA-receptor hypofunction induced by chronic KET administration (30 mg/kg IP for
14 consecutive days) did not significantly impact overall PV immunoreactivity within the
hippocampal structure compared to saline-treated controls. There were no significant effects of
treatment within CA1, CA3, or DG.
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Figure 3.6 Representative photomicrographs: Hippocampus
Representative photomicrographs taken from HPC CA1, CA3, and DG. As can be seen, chronic
KET administration, as compared to saline, did not alter overall PV immunoreactivity within
these HPC sub-regions. CA1 and CA3 were photographed at 20x magnification, while DG was
photographed at 10x magnification.
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Table 3.1: Descriptive Data

Prefrontal (Cingulate; n = 10)
Retrosplenial (n = 10)
Somatosensory (n = 10)

Saline

Ketamine

43.8 ± 7.9
47.5 ± 8.6
94.1 ± 8.1

56.6 ± 6.7
61.1 ± 7.9
99.4 ± 12.5

4.4 ± 0.4
2.7 ± 0.4
3.2 ± 0.5

5.0 ± 0.4
3.0 ± 0.4
2.6 ± 0.4

Hippocampus
CA1 (n = 30)
CA3 (n = 30)
DG (n = 20)

Descriptive data in the above table is expressed as M ± S.E.M. and represents the average
number of PV expressing cells per 1600µm² for each region. There were no significant
differences in average PV expression as a function of treatment (KET v. saline).
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CHAPTER 4
Behavioral experience and chronic ketamine administration differentially impact
parvalbumin expression in rats

4.1

Abstract

Parvalbumin (PV) expression within GABAergic inhibitory neurons is selectively
decreased within the prefrontal cortex and hippocampus (HPC) of postmortem tissue
from schizophrenic patients. It is generally accepted that aberrations in the overall
functionality of PV-containing inhibitory neurons contribute to cognitive impairments
characteristic of this disorder. Rodent models of cognitive impairment utilizing noncompetitive NMDA antagonists, such as ketamine (KET), are used to induce a state of
NMDA hypofunction within neocortical and HPC circuits underlying cognitive processes.
The literature exploring this phenomenon with regard to cognitive dysfunction is mixed,
with some reports indicating concomitant decreases in PV expression, with others
suggesting no role of PV alterations in cognitive phenotypes. The present study
provides characterization of PV expression in young (2-3 months) behaviorally trained
rats and the relationship between PV expression and cognitive performance. We
provide evidence for KET-induced cognitive impairments in a spatial water maze task, in
addition to a parallel decrease in PV expression selective to the HPC CA1 sub-region.
Based on the present data, we suggest that loss of PV expression in CA1 may underlie
KET-induced pathology, and that deficits seen in cognitive performance may be related
to decreases in PV expression in the HPC of young rats.
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4.2

Introduction
Deficits in cognition are the arguably the most pervasive and difficult to treat

impairments seen in schizophrenia (SCZ), yet the underlying neural mechanisms of
these deficits are poorly understood (O’Donnell, 2007; Vohringer et al., 2013). A prime
candidate underlying cognitive impairment is glutamatergic hypofunction within
prefrontal cortex and hippocampal (HPC) brain circuitry integral to these processes
(Moghaddam and Javitt, 2012). It is likely that decreased glutamatergic transmission
brought on by receptor hypofunction may indirectly impact other neuronal elements
within the affected circuitry, thereby giving rise to an array of characteristic symptoms
(Harrison and Weinberger, 2005; Lisman, 2012). Models of NMDA receptor
hypofunction (e.g. via the administration of NMDA-antagonist drugs) provide clues as to
the relationship between NMDA receptor hypoactivation and cognitive impairment, in
addition to the putative downstream neuropathological consequences () and have
provided insight into the interplay between NMDA receptors and GABAergic circuitry.
Recent findings implicate GABAergic inhibitory neurons in the pathophysiology of
SCZ cognitive impairment (Nakazawa et al., 2012; Inan et al., 2013); specifically those
expressing the calcium-binding protein (CBP), parvalbumin (PV). In post-mortem SCZ
brain tissue, PV expression is found to be selectively and significantly reduced in both
the prefrontal cortex (Beasley & Reynolds, 1997) and the HPC (Zhang & Reynolds,
2002). It is thought that the effects of NMDA-receptor hypofunction may actually be
localized to PV-containing GABAergic inhibitory neurons (Coyle, 2006; Carlen et al.,
2012). Thus, a specific hypofunction of glutamatergic input onto these neurons in key
brain circuits may underlie an overall decrease in the inhibition of principal excitatory
neurons, whose firing precision is essential to the processing and encoding of relevant
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information (Gonzalez-Burgos et al., 2011; Gonzalez-Burgos & Lewis, 2012; Rotaru et
al., 2012).
While the evidence in support of a link between NMDA hypofunction, impaired
cognition, and concomitant changes in PV expression in GABAergic neurons is
compelling, there are conflicts within the rodent literature. While a number of groups
have reported observed changes in PV expression following acute or chronic NMDA
hypofunction induced cognitive impairment (e.g. Keilhoff et al., 2004; Behrens et al.,
2007; Kittelberger et al., 2012), other groups report a lack of concomitant
neuropathological changes following similar preparations (e.g. Braun et al., 2007;
Benneyworth et al., 2011), or even increases in PV expression (e.g. Sabbagh et al.,
2013). Furthermore, it is possible that the training animals, in and of itself, in a cognitive
task may serve to modulate PV expression based on the complexity and time-span of
training, as indicated by previous observations in our lab (Corriveau, Master’s Thesis,
2013). This caveat is supported by compelling findings indicating an increase in PV
expression as a result of environmental enrichment (e.g. Iuvone et al., 1996; Komitova
et al., 2013). Thus, it is likely that PV may be differentially regulated based on a myriad
of factors including cognitive-behavioral training, chronic NMDA antagonism, and
developmental age, among others.
Previous work in our lab has outlined an important role for age in the density of
PV expression within the HPC (Corriveau, Master’s Thesis, 2013). Additionally, work
detailed in Chapter 2 of this dissertation provides further evidence of an age-dependent
decrease in PV expression from 1 to 6 and 12 month old rats. Data presented in
Chapter 3 indicate a chronic KET-induced impairment in cognitive performance in the
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absence of KET-related changes in PV expression. We posit that this lack of an effect
following KET treatment may be due to the fact that rats in the study were 6 months of
age – an age at which we have already observed very low baseline levels of PV. Based
on these data, we propose that younger rats e.g. 1-3 months of age) may show chronic
KET-induced cognitive impairment with a concomitant decrease in PV expression,
particularly because inhibitory circuits are likely still maturing (Monyer et al., 1994;
Scheetz & Constantine-Paton, 1994; Yu et al., 2006), and may therefore be more
susceptible to the deleterious effects of KET treatment (e.g., Huang et al., 2012).
Furthermore, previous research employing NMDA hypofunction models in younger
animals have described decreases in HPC PV expression (e.g., Braun et al., 2007).
In order to address the dynamic nature of PV expression based chronic NMDA
antagonism in a younger cohort of rats than previously examined in our lab, the present
study sought to characterize PV expression within the HPC and neocortex. In the
present work, we describe the impact of chronic KET administration on PV expression
in a delayed matching-to-sample radial water maze (DMTS-RWM) task, and provide
data indicating KET-induced cognitive impairments. Additionally, we provide evidence
for a significant KET-induced decrease in PV expression within HPC CA1. Taken
together, the findings of the present study suggest that cognitive-behavioral training –
while not necessarily mediating cognitive outcomes following NMDA antagonism – may
serve to buffer KET-induced changes in PV expression, at least within CA3 and DG
sub-regions of the HPC, though CA1 appears to be particularly susceptible to KETinduced impairments, and may underlie – to some extent – the cognitive impairment
seen in the DMTS-RWM task.
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4.3

Methods

4.3.1 Subjects
Sixteen male Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) aged
approximately 2-3 months were utilized for the current set of experiments. All rats were
individually housed in polycarbonate cages with food intake restricted to approximately
12 grams of rat chow per day and free access to water. Rats were housed in a
temperature and humidity controlled vivarium with a 12-hour light/dark cycle (lights on at
0800h) and all experienced normal husbandry procedures. Rats in this study
experienced behavioral training in a DMTS-RWM task beginning when rats were
approximately 1 month of age and continuing until sacrifice and tissue collection
(approximately 2.5 months of age). Half of the rats used for the present experiment
received a chronic regimen of KET (30 mg/kg IP; n = 8) or a comparable injection of
physiological saline (n = 8). All housing and experimental procedures were performed in
accordance with, and approved by, the University of Connecticut Institutional Animal
Care and Use Committee.
4.3.2 Behavioral testing – delayed matching-to-sample radial water maze task
Rats were trained and d tested in the delayed matching-to-sample radial water maze
(DMTS-RWM) cognitive-behavioral task to assess the impact of chronic KET
administration on cognitive performance. The task apparatus is comprised of a 140cm
diameter black fiberglass pool with a depth of 40cm. The pool houses eight black
removable stainless steel corridors measuring 14cm wide x 36cm long which extend
outwards from a central octagonal hub measuring 50cm in diameter. The pool is filled
with cool water (22 ± 2ºC) with corridor walls extending 16cm above water level. A
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removable 10cm diameter black PVC platform is submerged approximately 6cm below
the surface of the water and serves as a hidden escape route (‘goal’) from the pool.
One week after arrival into the colony, rats were given four days of standard
Morris water maze (four trials per day from each of four start locations to a fixed goal
position; beginning at approximately PD30) training to acclimate them to water escape
and the general testing procedure. On the fifth day, the goal location was moved to a
different location to test their reversal performance over four trials on that day. The
following week, rats were trained on a delayed matching-to-sample radial water maze
(DMTS-RWM) task (Chrobak et al., 2008). The current procedure involved one forced
sample trial each day followed by two test trials to the same fixed goal position (see
Figure 4.6A). The first test was at 5 minutes following the sample, with a second test to
the same goal position at 30 minutes following the sample. Rats were trained on this
procedure for 25 days.
At 60 days of age, rats began receiving chronic KET or comparable saline
treatment. On the first day of KET treatment rats were tested on the sample-test=test
procedure as described above (see Figure 4.1A), and were additionally tested on a
second set of sample-test trials (see Figure 4.1B). The initiation of the second sampletest trial within a day increased errors which typically manifest as proactive errors to the
first sample goal on any given day (see Chrobak et al., 2008). All rats were tested with a
5 minute delay between the sample and test on this second sample-test sequence.
Subsequently, all rats were tested for 14 consecutive days over the course of the 14
day KET, or comparable saline, treatment.
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4.3.3 Drug administration
Following continuous training in the DMTS-RWM task, rats began chronic KET
treatment consisting of 14 consecutive days of 30 mg/kg KET via IP injections (n = 8) or
a comparable injection of saline (n = 8). Injections were given at the same time each
day (between 4-6pm) for the duration of the treatment, and were administered
subsequent to DMTS-RWM testing, ensuring that the treatment would not directly
interfere with task performance.
4.3.4 Immunohistochemistry
Rats were anesthetized with Euthasol (pentobarbital sodium solution; 1mL via IP
injection) and transcardially perfused with ice-cold 0.9% physiological saline solution
immediately followed by ice-cold 3.7% paraformaldehyde solution. Following perfusion,
brains were removed and individually stored in scintillation vials filled with 3.7%
paraformaldehyde solution for 1 week. Prior to sectioning, brains were transferred into a
30% sucrose solution for cryoprotection. All brains were sliced into 60µm serial coronal
sections on a cryostat and stored in phosphate-buffered saline (PBS)-containing wellplates.
One series of tissue sections from each brain was selected to examine PV
immunoreactivity, with sections encompassing tissue approximately -2.5mm through 6mm and +2.5mm through +0.25mm relative to Bregma (Paxinos & Watson, 1997) to
include the septotemporal extent of the HPC and prefrontal cortex (anterior cingulate),
respectively. Refer to Figure 2.1 for section selection specifications. Free floating
sections were initially blocked in 5% normal goat serum (NGS; Jackson Immuno), 0.1%
triton-X, and PBS solution for 1 hour, followed by 3 five-minute rinses in PBS. Sections
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were then transferred into primary antibody solution (1:16000 anti-rabbit parvalbumin
polyclonal antibody (ABCAM), 0.1% triton-X, and PBS) for a 1 hour incubation period at
room temperature. Sections were then rinsed in PBS 3 times at five minutes each, and
transferred to secondary solution (horseradish peroxidase (HRP) labeled polymer antirabbit; DAKO) for a 1 hour incubation at room temperature. Following a final set of 3
five-minute rinses in PBS, sections were transferred into a diaminobenzidine (DAB)
chromogen solution (DAKO; Carpinteria, CA) for ten minutes to develop the stain.
Sections were mounted and dried on glass slides, then cover-slipped for microscopy
using DPX.
4.3.5 Quantification of PV expression
Microscopy slides containing tissue processed for PV protein expression was analyzed
using a Nikon Eclipse E600 (Melville, NY) upright microscope equipped with an Insight
SPOT digital camera (Diagnostic Instruments, Inc.). Photomicrographs of regions of
interest including: prefrontal cortex (anterior cingulate), HPC (including the CA1, CA3,
and DG sub-divisions), retrosplenial cortex, and somatosensory barrel field cortex, were
compiled and stored digitally for later analysis by a researcher blind to experimental
condition. To ensure precision in the quantification of PV-expressing cells within each
region of interest, photomicrographs were taken at either 20x magnification (CA1, CA3)
or 10x magnification (cortical areas, DG). Refer to Figure 2.2 for photomicrograph
sampling locations for each analyzed region.
Digital photographs were analyzed using ImageJ software (NIH), and the number
of PV-immunoreactive cells was quantified using macros written to automate particle
counting within each region of interest (refer to Figure 2.3 for an example of color-
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thresholding analysis performed). The sizes of the analyzed regions were as follows:
HPC CA1/CA3, 800µm²; HPC DG and cortical areas, 1600µm². The average number of
PV expressing cells for HPC CA1 and CA3 were normalized to represent the average
number of PV-positive cells per 1600µm² for cross regional comparisons and
consistency across data sets.
4.3.6 Statistical Analysis
4.3.6.1

Analysis of DMTS-RWM cognitive performance

Performance measures for the DMTS-RWM task include: 1) number of errors (average
number of incorrect corridor entries during the first test trial); 2) latency per choice (total
time to navigate to the goal divided by the number of choices made); and 3) first choice
latency (time to navigate to first corridor of test trial, regardless of choice). For the
purpose of the current analyses only mean error during test trials is presented.
In order to determine whether chronic KET administration significantly impaired
cognition in this task compared to saline-treated controls, split-plot two-way repeated
measures analyses of variance (RMANOVA, Wickens & Keppel, 1983; Kirk, 1982) were
conducted for treatment, trials (2 day blocks), and treatment by day interactions on the
number of errors averaged over 2-day blocks. Separate RMANOVA’s were conducted
on performance: 1) on the first sample-5 minute delayed test trial (7 x 2 day blocks (14
days)); 2) on the first sample-30 minute delayed test trial; and 3) on the second sample5 minute delayed test trial. Significant RMANOVA’s were subsequently followed by
Tukey’s HSD post-hoc analyses (Kirk, 1982) to compare the differences between KET
or comparable saline treatments on specific 2-day blocks.
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4.3.6.2

Analysis of PV expression

In order to explore differences in PV-immunoreactivity within each region, the number of
PV-expressing cells, as measured using ImageJ, was averaged for each rat in each rat,
and group means were computed for each treatment. This was done to determine
whether there were differences across HPC regions (collapsed across septotemporal
location), in addition to possible differences within neocortical regions as a function of
KET administration. The average number of PV expressing cells for each brain was
computed from 3-6 representative photomicrographs per region (2-3 photomicrographs
per hemisphere), and was collapsed across hemispheres as there were no significant
hemispheric differences in PV expression. Differences in PV expression based on
region and treatment were assessed using one-way Analysis of Variance (ANOVA) for
each region of interest, followed by post-hoc analyses where appropriate.

4.4

Results

4.4.1 DMTS-RWM performance is impaired by chronic KET treatment
4.4.1.1

First sample-5 minute delayed test

Following 25 days of training on the sample-5 minute delayed test-30 minute delayed
test procedure, rats were performing at a fairly high level, making 0.8-1.4 errors per day
as a group on the 5-minute delayed test trial and controls performed slightly better on
the second test (0.5-1.4 errors per day as a group). We observed no significant impact
of chronic KET treatment on performance in this “short” (5-minute) delayed test over 14
consecutive days of treatment as compared to saline controls. RMANOVA’s indicated
no treatment, trial (2-day blocks), or treatment by trial interactions (p’s < 0.4). See
Figure 4.1A.
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4.4.1.2

First sample-30 minute delayed test

Somewhat surprisingly, there was a significant impairment in the performance of the
chronic KET treated group as compared to saline controls, which was evident by day 56 of testing and was sustained over the remaining days of KET treatment. RMANOA’s
indicated a significant effect of treatment (F(1.7) = 14.92, p < 0.01), a significant effect
of trial (F(6,42) = 6.78, p < 0.01), in addition to a significant trial by treatment interaction
(F(6,42) = 4.77, p < 0.01). Post-hoc analyses indicated significant differences during the
day 5-6 block (p’s < 0.05) and all subsequent testing blocks during treatment period.
This finding contrasts with the absence of any memory deficits in 6 and 12 month old
rats performing similar tasks following chronic KET treatment without a specific
proactive interference procedure (2nd sample goal) within a day. See Figure 4.2B. It is
clearly evident that the age of the rats and/or the degree of training experienced may
explain the clear difference between this sample of 2-3 month old rats, and older rats
with many months of training on the DMTS-RWM task.
4.4.1.3

Second sample-5 minute delayed test

As expected, KET treated rats also exhibited a significant impairment in memory
performance during the specific proactive interference procedure during each day
(second sample-5 minute delayed test task). RMANOVA’s indicated a significant effect
of treatment (F(1,7) = 12.44, p < 0.01), a significant effect of trial (F(6,42) = 9.78, p <
0.001), and a significant trial by treatment interaction (F(6,42) = 7.68, p < 0.001). Posthoc analyses indicated significant differences during the day 7-8 block (p’s < 0.05) and
all subsequent testing blocks during the treatment period (see Figure 4.2C).
4.4.2 Effects of chronic KET treatment on PV expression in the neocortex
To determine the effect of chronic KET treatment on PV expression within the
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neocortical areas of interest, a one-way ANOVA was conducted. Analyses revealed that
there were no significant effects within any cortical region of interest including prefrontal
(anterior cingulate; F(1,15) = 0.06, p = 0.81), retrosplenial (F(1,15) = 0.29, p = 0.60), or
somatosensory (F(1,15) = 0.003, p = 0.96) cortices (see Figure 4.3 for summary, and
Figure 4.4 for representative photomicrographs).
4.4.3 Effects of chronic KET treatment on PV expression in the HPC
A significant effect of chronic KET administration was seen specifically within the CA1
region of the HPC, with no significant effect of treatment in CA3 or DG regions. To
explore the effect of chronic KET administration on PV expression within the HPC subregions, a one-way ANOVA was conducted for each sub-region (CA1, CA3, DG).
Analysis revealed a significant effect of chronic KET administration exclusively within
CA1 (F(1,47) = 10.83, p < 0.01), such that KET-treated rats had significantly less PV
expression than saline-treated controls (Figure 4.5). There were no effects of treatment
seen in CA3 (F(1,47) = 1.56, p = 0.22) or DG (F(1,31) = 0.68, p = 0.42). See Figure 4.5
for summary of data, and Figure 4.6 for representative photomicrographs of the HPC
regions of interest. Descriptive data for all regions can be seen in Table 4.1.

4.5

Discussion

The current findings generally provide support to previous work in our lab indicating that
PV expression is dynamically modulated by a myriad of influences (e.g. age; see
Chapter 2). We provide further nuance to the dynamic nature of PV expression within
the data presented herein, suggesting that chronic KET administration impairs cognition
with a concomitant decrease in PV expression within the HPC. Previously, we noted
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that in adult rats, chronic KET administration impairs cognitive performance, but does
not change PV expression within the HPC (see Chapter 3). These null data were seen
in adult (6 months) rats; conversely, we find in the present study – which utilized 2-3
month old young rats – that impaired cognition and decreases in PV expression show a
clear relationship which is likely age-dependent. The lack of an effect of KET treatment
on PV expression within the neocortex was expected based on our previous findings,
and is in line with a small number of studies indicating no change in cortical PV
expression as a function of NMDA antagonism (e.g. Benneyworth et al., 2011).
Within the present data, it is clear that chronic KET administration not only
impaired cognition, but also decreased CA1 PV expression, thereby revealing PV as a
possible underlying mechanism in KET-induced cognitive impairment (Gonzalez-Burgos
& Lewis, 2012). Importantly, we see this effect in the current set of data which was done
in young (approximately 2-3 months of age) rats that were behaviorally trained, while we
do not see this effect in adult rats (Chapter 3). While age is likely driving the effect seen
in chronically KET treated rats in the present and previous studies conducted in our lab,
it is also possible that behavioral training may buffer some of the deleterious effects of
KET treatment. The present data does suggest that behavioral training may buffer KETinduced loss of PV expression, minimally within the CA3 and DG regions of the HPC
(see Figure 4.5), which is in line with literature describing increases in PV expression
following enrichment (e.g., Iuvone et al., 1996; Komitova et al., 2013). However,
additional research is warranted to determine the developmental time course of KET
susceptibility to HPC PV expression decreases, in addition to a controlled study
specifically aiming to determine the interaction between age and behavioral training.
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Overall, the present study describes chronic KET mediated deficits in DMTSRWM cognitive performance when compared to saline controls, with a concomitant PV
decrease selectively seen in HPC CA1 of KET treated rats. Though we observed
decreases in PV expression in CA1, it remains possible that cognitive impairment may
be relatively independent of aberrations in PV expression within the cortex and HPC
inhibitory circuitry, as many regions appeared resilient to the KET treatment. As PV
expression has been repeatedly linked to the coordination of neural excitability integral
to sustaining cognitive processes, we believe it is unlikely that the behavioral
impairments in the DMTS-RWM task are independent of KET- induced changes in PVcontaining neuron functionality (Carlen et al., 2012; Gonzalez-Burgos et al., 2015). We
must also consider the fact that the rats used in the current study were approximately 2
months of age, and previously we have noted that 1 month old rats have significant
higher PV expression overall than 6 month old rats. It stands to reason that 2 month old
rats would have a similar high density of PV expression compared to adult rats, and
therefore a KET induced decrease might be more apparent due to higher baseline
levels of expression (see Chapter 2). In order to better characterize the effect of chronic
KET administration on PV expression in HPC and neocortex, examination of PV
expression following KET treatment at different developmental ages, in addition to
behaviorally trained and naïve groups, is warranted.

4.6

Conclusion

In summary, the present work provides compelling evidence for schizophrenic-like
cognitive deficits in a DMTS-RWM task in rats following chronic treatment with KET
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compared to saline controls. Additionally, we provide data showing a parallel decrease
in PV expression within the CA1 region of the HPC. These findings also suggest that
cognitive-behavioral training may serve to buffer possible deleterious effects of chronic
KET administration, as there were no effects seen in CA3 and DG HPC sub-regions as
a function of treatment. This, in turn, ostensibly supports the use of cognitive-behavioral
therapies in SCZ cognitive symptom mediation. Based on the current data, and in
comparison with data observed in Chapter 3, we propose that young rats (e.g. 1-3
months of age) are more likely to show KET-induced deficits in PV expression than
adult rats. This differential effect of age may be due to the developmental trajectory of
inhibitory circuit maturation, making a developing circuit more prone to insult than an
established one. To better understand these nuances in the dynamic nature of the PV
protein, we propose that additional investigations systematically exploring the impact of
age in mediating chronic KET-induced changes be carried out.
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Figure 4.1: Delayed matching-to-sample radial water maze task procedure
For the first month of training, rats were trained in the DMTS-RWM task every day, with an initial
forced sample trial to learn the goal location for the day, followed by a 5 minute delayed test,
which was then followed by a 30 minute delayed second test; the correct goal for both tests
being the goal shown in the forced sample (A). Upon beginning chronic KET treatment, rats
continued the standard daily trials (A), in addition to the introduction of a new, second goal
location for the day given in a second forced sample and followed by a 5 minute delayed test
(B). This second set of trials was separated by an approximately 30 minute delay between the
2nd test trial and the 2nd forced sample. This procedure allowed for the investigation of how
chronic KET treatment influences DMTS-RWM cognitive performance, as well as examine
whether rats can discriminate between a previous within-day goal location and the most recent
location.
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Figure 4.2: Chronic KET impairs DMTS-RWM performance
Rats were assessed for cognition on the DMTS-RWM task (as described in Figure 4.1), and
performance was analyzed based on the mean number of errors made before locating the most
recent goal location. Chronic KET administration did not impair task performance during the
initial 5 minute delayed test (A), but significantly impaired performance beginning on Day 6
during the first 30 minute delayed test (B). During the trials initiated at the start of KET
treatment, a significant difference in performance emerged starting at Day 8, which continued to
the final day of testing (Day 14), such that the control rats learned to go to the most recent goal
location, while KET treated rats made significantly more errors than controls (C). These findings
indicate a role for KET enhanced proactive interference on performance.
*p < 0.05
**p < 0.01
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Figure 4.3: No effect of chronic KET administration on cortical PV expression in
behaviorally trained rats
Despite showing impairment in cognitive processes, rats that were treated with chronic KET did
not show changes in average PV expression within the prefrontal (anterior cingulate) cortex,
retrosplenial cortex, or the somatosensory barrel fields compared to saline-treated controls.
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Figure 4.4: Representative photomicrographs of PV expression in neocortical regions of
interest
There were no significant effects of chronic KET treatment on PV expression within any
neocortical regions of interest observed (prefrontal, retrosplenial, or somatosensory).
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Figure 4.5: Chronic KET administration decreases CA1 PV expression
Chronic KET administration significantly decreased the number of PV expressing neurons in the
CA1 sub-region of the HPC. However, this effect was selective for CA1, as CA3 and DG subregions did not show an effect of KET treatment.
*p < 0.01
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Figure 4.6: Representative photomicrographs of PV expression within the HPC
Chronic KET administration significantly decreased average PV expression exclusively within
the CA1 sub-region of the HPC. There was no effect of KET treatment on PV expression within
CA3 or DG sub-regions.
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Table 4.1: Descriptive Data

Prefrontal (Cingulate; n = 8)
Retrosplenial (n = 8)
Somatosensory (n = 8)

Saline

Ketamine

107.4 ± 9.2
92.0 ± 18.1
68.1 ± 9.5

104.8 ± 5.9
80.4 ± 12.1
68.8 ± 9.0

15.5 ± 1.4
9.5 ± 1.5
3.3 ± 0.6

10.0 ± 0.9*
7.1 ± 1.2
4.0 ± 0.6

Hippocampus
CA1 (n = 24)
CA3 (n = 24)
DG (n = 16)

Descriptive data in the above table is expressed as M ± S.E.M. and represents the average
number of PV expressing cells per 1600µm² for each region (n’s indicated above).
An asterisk (*) following the M±SEM indicates that the PV expression is significantly different
from saline control at the p < 0.01 level

84

CHAPTER 5
Age and time of sacrifice mediate expression of the calcium-binding protein
parvalbumin in a model of NMDA hypofunction

5.1

Abstract

A marked decrease in the expression of the calcium-binding protein, parvalbumin (PV),
has been a consistently replicated finding in postmortem tissue of patients with
schizophrenia. This reduction is selective to PV, and is not seen in other calciumbinding proteins (e.g. calretinin), and alterations are exclusively seen within the
prefrontal cortex and hippocampus of patients. Rodent models of NMDA-receptor
hypofunction utilizing non-competitive NMDA antagonist drugs such as ketamine (KET) to
induce schizophrenic-like cognitive impairments show a comparable decrease in PV
immunoreactivity, which is often considered a marker of underlying neuropathology. However,
previous studies looking at the effects of chronic KET administration on cognitive impairment
and concomitant changes in PV expression are contradictory, with findings suggesting
decreased, increased, or even no change in PV expression. Upon examination of the
procedures used across studies it is clear that there many inconsistencies, particularly with
regard to the age of animals used, as well as the timeline of tissue collection. In order to better
understand the possibility of methodological differences impacting PV expression, the present
study specifically investigated the impact of age and time of sacrifice/brain tissue collection in
behaviorally-naïve male Sprague-Dawley rats following chronic KET treatment (14 consecutive
days of 30 mg/kg IP) compared to controls. Our findings suggest a dynamic interaction between
age and time of sacrifice on prefrontal cortical and hippocampal PV expression based on
treatment. Additionally, we provide compelling evidence for age-related differences in PV
response to chronic KET treatment, such that 1 month old rats exhibit decreased PV, while
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naïve adult rats show increased PV following KET treatment. Based on our data, we propose
that PV expression is a highly dynamic marker, and that changes in expression following NMDA
antagonist treatment should be considered in the context of the age of the animals used.
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5.2

Introduction
Pervasive cognitive deficits are a hallmark of schizophrenia (SCZ) and are

predictive of long term outcome and functionality in patient populations (Elvevag &
Goldberg, 2000; Keefe & Harvey, 2012).Postmortem findings in patients have revealed
a selective decrease in the expression of the calcium-binding protein (CBP),
parvalbumin (PV), within the prefrontal cortex (Beasley & Reynolds, 1997) and
hippocampus (HPC; Zhang & Reynolds, 2002). PV is localized to GABAergic inhibitory
neurons targeting the perisomatic region of postsynaptic pyramidal cells, and plays a
key role in the coordination of neural synchrony within frontal and limbic circuitry
important for maintaining effective cognitive and memory processes (Gonzalez-Burgos
et al., 2015).
Rodent models of schizophreniform cognitive impairments have been integral to
advancing our understanding of the pathophysiology underlying these deficits and
provide insight into their putative neural mechanisms. NMDA hypofunction induced by
NMDA antagonist pharmacological agents (e.g. ketamine, MK-801, PCP) is a widely
accepted and used model in large part to its ability to replicate the cognitive-behavioral
impairments characteristic of SCZ (Meltzer et al., 2013). Additionally, administration of
NMDA antagonist drugs have been shown to replicate neuropathological features of the
disorder; specifically, many groups have observed a decrease in PV expression
prefrontal and HPC brain regions following acute and/or chronic administration of these
drugs (Adell et al., 2012). Despite general agreement that decreased PV expression
following pharmacologically induced NMDA hypofunction is a valid model of
schizophrenic neuropathology, there exists a growing number of studies presenting
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conflicting findings, calling into question the aptness of utilizing PV as a marker of
pathology.
Within the literature discrepancies regarding the outcomes of NMDA antagonism
on neuropathology, particularly PV expression, are apparent with some groups
indicating significant decreases in PV expression following treatment (e.g. Kittelberger
et al., 2012), and some reporting no change (e.g. Benneyworth et al., 2011).
Interestingly, upon examination of the methods employed across various studies, it
clear that differences in methodology exist, including: 1) whether or not behavioral
assays were used to assess concomitant cognitive impairment; 2) the age of the
animals used in the studies; and 3) the timeline of tissue collection following treatment
and/or behavioral assays. Previously, we have provided evidence suggesting that
behavioral training increases the expression of PV expression across brain regions
(Corriveau, Master’s Thesis, 2013; in agreement with Gomes da Silva et al., 2010;
Urakawa et al., 2013), and therefore the act of behavioral experience may serve to
mask possible NMDA antagonist-induced decreases in PV(see Chapters 3 and 4).
Findings indicating developmental changes in PV expression from young to adult
rodents provide a compelling argument for considering age as a factor, since there
appears to be a decrease in PV expression within the HPC in adult compared to young
animals (see Chapter 2; Corriveau, Master’s Thesis, 2013; in agreement with De Jong
et al., 1996). Time of tissue collection is also likely to be a significant mediator of PV
immunoreactivity, as emerging evidence suggests that PV phenotype begins to recover
as a function of time since treatment cessation (Behrens et al., 2008). In order to better
understand the normative relationship between PV and these factors, the present study
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sought to investigate: 1) changes in PV expression from 1 to 6 month old behaviorally
naïve rats; 2) the impact of chronic KET administration on PV expression as a function
of age; and 3) the role of tissue collection time line post KET cessation on PV
expression. Here, we provide compelling evidence suggesting a differential effect of
chronic KET administration based on age, such that 1 month old rats show significant
decreases in PV expression, whereas 6 month old rats show a pattern of increased PV
expression. Furthermore, we provide evidence suggesting a role of tissue collection
timeline on PV immunoreactivity. Our work suggests that PV expression is highly
dynamic and can be mediated by a myriad of factors, and therefore may not be a
reliable marker of pathology.

5.3

Methods

5.3.1 Subjects and drug administration
Thirty male Sprague Dawley rats sourced from Charles River Laboratories (Wilmington,
MA) were used for the present study and were aged 1 month (approximately PD30; n
=15) and 6 months (n = 15). Prior to pharmacological manipulations, all rats were
individually housed in polycarbonate caging with access to food and water ad libitum.
Rats were housed in a temperature and humidity controlled vivarium with a 12 hour
light/dark cycle (lights on at 0800h) and were exposed to normal husbandry procedures,
but were otherwise behaviorally naïve. Subsets of rats from each age group (1- and 6months) were assigned to one of 3 distinct treatment groups consisting of: 1) chronic
ketamine regimen with tissue collection immediately following treatment cessation (30
mg/kg IP; n = 5 per age group); 2) chronic ketamine regimen with tissue collection
delayed 10 days post treatment cessation (30 mg/kg IP; n = 5 per age group); or 3)
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comparable IP injection treatment of physiological saline (n = 5 per age group). All
housing and experimental procedures were performed in accordance with, and
approved by, the University of Connecticut Institutional Animal Care and Use
Committee.
5.3.2 Immunohistochemistry
Rats were anesthetized with Euthasol (pentobarbital sodium solution; .5 – 1mL via IP
injections) and transcardially perfused with ice-cold 0.9% physiological saline solution
immediately followed by ice-cold 3.7% paraformaldehyde solution. Following perfusions,
brains were removed and individually stored in scintillation vials filled with 3.7%
paraformaldehyde solution for 1 week. Prior to sectioning, brains were transferred into a
30% sucrose solution for cryoprotection. All brains were sliced into 60µm serial coronal
sections on a cryostat and stored in phosphate-buffered saline (PBS)-containing wellplates for storage prior to immunohustochemical procedures.
One series of tissue sections from each brain was selected to examine PV
immunoreactivity, with sections encompassing tissue approximately +2.5mm through
+0.25mm from Bregma to include anterior cingulate cortex, and -2.5mm through -6mm
relative to Bregma to include the septotemporal extent of the HPC (Paxinos & Watson,
1997). Free floating sections were initially blocked in 5% normal goat serum (NGS;
Jackson Immuno), 0.1% triton-X, and PBS solution for 1 hour, followed by 3 five-minute
rinses in PBS. Sections were then transferred into primary antibody solution (1:16000
anti-rabbit parvalbumin polyclonal antibody (ABCAM), 0.1% triton-X, and PBS) for a 1
hour incubation period at room temperature. Sections were then rinsed in PBS 3 times
at five minutes each, and transferred to secondary solution (horseradish peroxidase
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(HRP) labeled polymer anti-rabbit; DAKO) for a 1 hour incubation at room temperature.
Following a final set of 3 five-minute rinses in PBS, sections were transferred into a
diaminobenzidine (DAB) chromogen solution (DAKO) for ten minutes to develop the
stain. Sections were then mounted and dried on glass slides, then cover-slipped for
microscopy using DPX.
5.3.3 Quantification of PV expression
Slides containing tissue processed for PV immunoreactivity were analyzed using a
Nikon Eclipse E600 (Melville, NY) upright microscope equipped with an Insight SPOT
digital camera (Diagnostic Instruments, Inc.). Photomicrographs of regions of interest
including: prefrontal cortex (anterior cingulate), retrosplenial cortex, somatosensory
barrel fields, and HPC (including the CA1, CA3, and DG sub-divisions; as sampled in
Nomura et al., 1997), were catalogued and stored digitally for analysis by a researcher
blind to treatment and age (refer to Figure 2.1 for sampling examples). To ensure
precision in the quantification of PV-expressing cells within each region of interest,
photomicrographs were taken at either 20x magnification (CA1, CA3) or 10x
magnification (cortical areas, DG). Refer to Figure 2.2 for photomicrograph sampling
locations for each analyzed region.
Digital photographs were analyzed using ImageJ software (NIH), and the number
of PV-immunoreactive cells was quantified using macros written to automate particle
counting within each region of interest (refer to Figure 2.3 for an example of colorthresholding analysis performed). The sizes of the analyzed regions were as follows:
HPC CA1/CA3, 800µm²; HPC DG and cortical areas, 1600µm². The average number of
PV expressing cells for HPC CA1 and CA3 were normalized to represent the average
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number of PV-positive cells per 1600µm² for cross regional comparisons and
consistency across data sets.
5.3.4 Statistical Analysis of PV expression
In order characterize the differences in PV immunoreactivity based on treatment and
time of sacrifice, the average number of PV expressing cells was calculated for each rat
as measure using ImageJ, and group means were computed for each treatment group
within each age group. This was done across brain regions for each rat, and for each
region the average number of PV cells was computed from 3-6 photomicrographs per
region (2-3 photomicrographs from each of the left and right hemispheres). Data was
collapsed across hemispheres for all brain regions as there were no significant
hemispheric differences in expression. Within the HPC sub-regions (CA1, CA3, DG)
averages for septotemporal regions (septal, MST, temporal) were considered individual
samples and contributed to overall averages for respective regions. Differences in PV
immunoreactivity were assessed using separate one-way ANOVA analyses for 1 and 6
month old animals to determine whether there were changes within each group as a
function of treatment and/or time of sacrifice. An additional one-way ANO VA was
conducted between age groups to determine baseline differences in PV expression in
saline-treated controls as a function of age. Significant effects were followed up with
post-hoc analyses where appropriate.

5.4

Results

5.4.1 Age-related effects
Overall, there was a significant effect of developmental age, which was especially
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apparent in the control rats, such that 1 month old rats had significantly higher levels of
PV expression within the HPC and prefrontal (cingulate) cortex regions than 6 month
old rats. Furthermore, 1 month old control rats had significantly higher levels of PV
across all regions of the HPC compared to 1 month old KET treated rats. Conversely,
KET treated 6 month old rats showed a general trend toward an increase in PV
expression compared to 6 month controls. Additionally, KET administration appears to
equalize PV expression when comparing 1 and 6 month old KET treated rats. Thus, our
observations consistently evidence age-related decreases in PV expression most
prominent in the HPC, and an interaction between age and KET treatment on PV
expression across multiple brain regions.
5.4.1.1

Neocortex Results

Analyses revealed a significant decrease in PV expression in 6 month old compared to
1 month old saline controls exclusively within the prefrontal (cingulate) cortex (F(1,9) =
8.81, p < 0.02; Figure 5.1). No effect of age was seen in the retrosplenial cortex (F(1,9)
= 1.83, p = 0.21), or in the somatosensory barrel fields (F(1,9) = 2.29, p = 0.17).
Additionally, there was no effect of age observed between 1 and 6 month old rats in the
KET group that was immediately sacrificed, or the KET group that was sacrificed 10
days post drug cessation (all p’s > 0.05). For representative photomicrographs see
Figure 5.2.
5.4.1.2

Hippocampus Results

Within the HPC, there was an overall decrease in PV expression as a function of age,
such that 6 month old rats expressed significantly less PV than 1 month old rats in the
control condition. This age-related decrease was seen in CA1 (F(1,29) = 9.45, p < 0.01),
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CA3 (F(1,29) = 8.63, p < 0.01), and DG (F(1,19) = 12.62, p < 0.01). Age-related
alterations in PV expression were only observed in controls, as there were no significant
differences seen as a function of age in either of the KET groups (immediate or delayed
sacrifice; all p’s > 0.05). See Figure 5.3 for summary of finding in the HPC, Figure 5.4
for representative photomicrographs, and Table 5.1 for descriptive statistics.
5.4.2 KET administration and time of sacrifice in 1 month old rats
5.4.2.1

Neocortex Results

KET administration did not significantly impact the number of PV expressing cells within
the neocortical regions of interest, nor did time of sacrifice (immediate or delayed post
drug-cessation) in 1 month old rats (Figure 5.5A). Analyses revealed no significant main
effect of treatment in the prefrontal (anterior cingulate) cortex (F(2,14) = 2.33, p = 0.14),
retrosplenial cortex (F(2,14) = 1.15, p = 0.35), or somatosensory barrel fields (F(2,14) =
0.87, p = 0.44). Representative photomicrographs can be seen in Figure 5.2.
5.4.2.2

Hippocampus Results

There was a significant decrease in PV expression as a function of KET
treatment, and this decrease was seen in both immediate and delayed tissue collection
groups and was significant at all levels of the HPC: CA1 (F(2,44) = 3.97, p < 0.05), CA3
(F(2,44) = 5.52, p < 0.01), and DG (F(2,29) = 5.68, p < 0.01). Post-hoc LSD analysis of
1 month old CA1 PV expression as a function of treatment revealed that saline controls
had significantly higher expression than immediate and delayed KET groups (p’s <
0.05), but that KET groups did not differ from one another (p = 0.80). Within CA3 and
DG, PV expression in control rats was significantly higher than in immediate and
delayed KET groups (p’s < 0.01), with KET groups not differing from each other (p =
0.96 and 0.94, respectively). Data summary can be seen in Figure 5.6, and
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representative photomicrographs can be found in Figure 5.4.
5.4.3 KET administration and time of sacrifice in 6 month old rats
5.4.3.1

Neocortex Results

PV expression in 6 month old rats was not significantly altered by treatment within the
neocortical regions of interest (Figure 5.5B).There were no significant main effects for
treatment in prefrontal (anterior cingulate) cortex (F(2,14) = 1.35, p = 0.30), retrosplenial
cortex (F(2,14) = 0.89, p = 0.44), or somatosensory barrel fields (F(2,14) = 0.57, p =
0.58).
5.4.3.2

Hippocampus Results

Generally, there was no effect of treatment in 6 month old rats within the HPC subregions, with the exception of DG. However, there appears to be a trend toward an
increase in overall PV expression in 6 month old rats treated with KET (Figure 5.6).
Analyses revealed no significant effect of treatment in CA1 (F(2,44) = 1.77, p = 0.18) or
CA3 (F(2,44) = 1.41, p = 0.26) of 6 month old rats, regardless of tissue collection
timeline. However, the general increase in PV expression as a function of KET
treatment reached significance in DG (F(2,29) = 4.61, p < 0.05), such that both the
immediate and delayed groups had significantly more PV than controls (p’s < 0.05 and
0.01, respectively).

5.5

Discussion

Overall, the present study provides compelling evidence supporting a selective agerelated decrease in PV expression within the prefrontal (cingulate) cortex. This cortical
finding is in addition to the robust age-related decrease in PV expression within the
HPC, which was non-specific and seen in all 3 sub-regions observed (CA1, CA3, DG).
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The present work also presents a novel dissociation between the effects of chronic KET
administration based on the age of the animal being treated. However, our findings
suggest that time of sacrifice does not have a significant impact on PV expression in
either age group, though the data appears to suggest a possible period of recovery
when rats are sacrificed at a delayed time point post drug cessation. Here, we discuss
the main findings observed in this work, including: 1) age is a significant factor in
normative baseline PV expression; and 2) KET administration differentially modulates
PV expression based on age.
5.5.1 Age significantly impacts normative PV expression
In the present work we provide strong evidence for a developmental decrease in PV
expression, which is very clear when comparing 1 and 6 month old control groups.
These findings are in strong agreement with work presented in this dissertation (see
Chapter 2), as well as findings previously presented from our lab (Corriveau, Master’s
Thesis, 2013). Within the literature, there have been few reports describing age-related
changes in PV expression, but of those available, the findings suggest a clear role of
age in regulating PV expression (e.g., Lolova & Davidoff, 1992; Miettinen et al., 1993;
Vela et al., 2003; Lee et al., 2013). The present findings provide clarity to this body of
work, as the rats utilized in the current study were behaviorally naïve, whereas many
studies employ behavioral assays on their subjects which likely changes baseline PV
expression due to experience/enrichment (Iuvone et al., 1996; Komitova et al., 2013).
These robust alterations in PV expression as a function of age should be thoroughly
considered, as differences in baseline expression can interfere with experimental
manipulations, leading to lack of validity as well as difficultly in interpreting and
generalizing results.
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5.5.2 Chronic KET treatment differentially impacts PV expression based on age
Acute and/or chronic KET administration is often linked to decreases in PV expression
comparable to those seen in schizophrenic postmortem brain tissue. However, the fact
that some studies find decreases in PV expression (e.g. Kittelberger et al., 2012), while
others find no change (e.g. Benneyworth et al., 2011) following KET treatment begs the
questions as to whether there may be additional factors impacting the reactivity of PV to
such treatments. The present findings provide clear evidence indicating that age plays a
key role in post-KET treatment PV expression.
Our work indicates a differential role of KET treatment that is specific to the age
of the animals receiving the treatment. Specifically, we see clear evidence for a
decrease in PV expression within 1 month old chronically KET treated rats compared to
controls, which is in agreement with previous findings (e.g. Kittelberger et al., 2012).
Conversely, we describe an opposite effect in 6 month old rats, such that those treated
with KET show a general trend toward an increase in PV expression compared to
controls, which reached significance in the DG. The significant elevation in PV
expression within the DG seen in the current study has not been well documented in the
literature, but is in agreement with a report by Sabbagh and colleagues (2013) reporting
an increase in HPC PV expression in adult rats following chronic KET administration
similar to that employed herein. A possible explanation for KET-induced increases in PV
expression in 6 month old rats exclusively within the HPC may be due to KET’s ability to
promote neurogenesis within the HPC (Keilhoff et al., 2004); a phenomenon which may
also explain increases in PV seen in our lab as a result of cognitive-behavioral
enrichment (Corriveau, Master’s Thesis, 2013).
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5.6

Conclusion

The present work elucidates upon the importance of age on PV expression within the
prefrontal cortex and HPC in rodents, and highlights the need for controlling for this
variable when examining KET-oriented models of SCZ dysfunction. Additionally, we
provide clear evidence indicating that KET-induced changes in PV expression may be
exclusively seen in young rats, and that the timeline of administration is likely crucial to
understanding the relationship between PV and KET-induced cognitive impairments. To
our knowledge, this is the first time a differential effect of KET as a function of
developmental age has been systematically described, and provides important nuance
to the literature describing KET-induced changes in PV expression. Additional
investigation into the impact of chronic KET administration on concomitant cognitivebehavioral impairment across differing age groups is warranted in order to better
understand the role of PV in regulating cognitive processes, and whether these
processes may be sensitive to aging.

98

Figure 5.1: PV expression is selectively decreased in the prefrontal cortex in 6 month old
controls
PV expression within the prefrontal (cingulate) cortex of 6 month old behaviorally naïve salinecontrols was significantly decreased compared to 1 month old behaviorally naïve salinecontrols. This decrease was selective for the prefrontal cortex, and was not seen in other
neocortical regions observed.
*p < 0.05
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Figure 5.2: Representative photomicrographs of neocortical regions of interest
Within the neocortical regions of interest, there was a significant effect of age in the prefrontal
(cingulate) cortex (A), with no effect of age in the retrosplenial (B) or somatosensory (C)
cortices. In the prefrontal cortex, 1 month old controls had significantly higher PV expression
than 6 month old controls. There was no effect of treatment in any of the regions for either age
group. Photomicrographs were taken at 10x magnification.
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Figure 5.3: Age-dependent decline in PV expression in control rats
In the HPC, there is a significant age-dependent decrease in PV expression from 1 month to 6
month old control rats. This decline in PV expression as a function of age is significant across all
HPC sub-regions: CA1 (A), CA3 (B), and DG (C). There was no effect of age on PV expression
in rats chronically treated with KET at either the immediate or delayed sacrifice time points.
*p < 0.05
**p < 0.01
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Figure 5.4 Representative photomicrographs of HPC regions of interest
1 month old rats had significantly higher PV expression than 6 month old rats in CA1 (A), CA3
(B), and DG (C) in the control condition. There were no significant effects of age in any of the
KET treated groups (immediate or delayed time of sacrifice post cessation). There was a
significant decrease in PV expression in 1 month old rats in KET (immediate and delayed)
treated rats compared to controls. In 6 month old rats treated with KET (immediate and delayed)
there was a significant increase in PV expression compared to controls. Photomicrographs of
CA1 (A) and CA3 (B) were taken at 20x magnification, while DG (C) photomicrographs were
taken at 10x magnification.
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Figure 5.5: Neocortical PV expression was not significantly altered by KET treatment or
time of sacrifice
No significant changes in PV expression were observed in neocortical regions of interest in 1
(A) or 6 (B) month old rats, regardless of KET treatment or time of tissue collection.
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Figure 5.6: PV expression is mediated by age and treatment condition
1 month old rats showed a significant reduction in PV expression as a function of treatment,
such that KET treated rats in both the immediate and delayed groups was significantly lower
than saline controls in CA1 (A), CA3 (B) and DG (C). There was no significant change in PV
expression in these regions based on time of sacrifice. In 6 month old rats, there was no effect
of treatment condition in CA1 (A) or CA3 (B). However, in DG (C) there was a significant
increase in PV expression as a result of KET treatment, and this increase was stable regardless
of tissue collection timeline.
*p < 0.05
**p < 0.01
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Table 5.1: Descriptive Data
1 Month

6 Months

Control

Immediate

Delayed

Control

Immediate

Delayed

103.9 ± 15.5
82.9 ± 8.1
92.1 ± 11.4

73.5 ± 7.8
66.6 ± 10.0
71.4 ± 14.1

81.7 ± 3.9
79.1 ± 4.7
86.7 ± 6.6

44.5 ± 12.6
61.6 ± 13.5
57.0 ± 20.2

45.8 ± 11.7
70.2 ± 12.2
56.4 ± 16.9

69.4 ± 12.0
84.0 ± 10.0
78.5 ± 11.6

12.6 ± 1.2
12.2 ± 1.4
7.1 ± 1.1

8.7 ± 1.0*
7.5 ± 1.2*
3.9 ± 0.4*

8.3 ± 1.3*
7.1 ± 1.1*
4.0 ± 1.9*

7.7 ± 1.0
6.6 ± 1.3
2.6 ± 0.7

10.6 ± 1.9
9.2 ± 1.7
4.3 ± 0.5*

11.0 ± 0.9
9.5 ± 0.9
5.0 ± 1.7*

Neocortex (n’s = 5)
Prefrontal (cingulate)
Retrosplenial
Somatosensory
Hippocampus
CA1
CA3
DG

(n’s = 15)
(n’s = 15)
(n’s = 10)

Descriptive data in the above table is expressed as M ± S.E.M. and represents the average
number of PV expressing cells per 1600µm² for each region of interest (n’s indicated in table).
An asterisk (*) following the M ± S.E.M. indicates that the PV expression is significantly different
from saline controls within the age group. Bold M ± S.E.M. within the 6 month old data indicates
that the average PV expression for that region is significantly decreased compared to 1 month
olds rats.
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CHAPTER 6
Discussion

6.1

Summary of findings

Overall, the current work sheds light on the need for considering age in rodent models
of psychiatric disorders to account for the dynamic expression of neuronal markers –
such as parvalbumin (PV) – throughout the lifespan. This is evidenced through multiple
results indicating significant decreases in PV expression in adult rats compared to high
baseline levels of PV expression in adolescent rats. Additionally, the present findings
indicate that age and behavioral training interact with chronic ketamine (KET)
administration. Specifically, we describe: 1) that chronic KET administration decreases
PV expression in 1 month old rats, while it appears to increase PV expression in 6
month old rats; and 2) chronic KET administration significantly impairs cognitive
performance in the DMTS-RWM task in both young and adult rats, but only young rats
show concomitant decreases in PV expression. We also report herein that the effects of
age and behavioral experience appear to be negated when rats are given a chronic
KET treatment, . Together, the present work systematically describes the dynamic
nature of PV expression across the lifespan, and provides compelling evidence for: 1) a
significant age-dependent decline in PV expression from adolescent to adult rats; 2)
differential impact of chronic KET administration on PV expression dependent on age;
and 3) a role for cognitive-behavioral training/experience in the modulation of PV
expression across multiple brain regions.
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6.2

Age-related effects on parvalbumin expression

The present findings from Chapter 1 of this dissertation provide evidence for age (1, 6,
12 months), regional (CA1, CA3, DG) and septotemporal location (septal, MST,
temporal) dependent variation in PV expression within the HPC. Conversely, we do not
observe significant age-dependent variation in PV expression within neocortical and
striatal regions. These findings are discussed with reference to their regional and agedependent differences below. The present work provides the first systematic
characterization of PV expression within the HPC in key sub-regions and across the
entire septotemporal axis as a function of age; a topic poorly characterized within the
literature.
Age as a robust determinant of PV expression is perhaps one of the most
compelling and interesting findings described in this dissertation, in addition to being a
factor that appears to interact with various other factors to dynamically modulate PV. In
addition to the significant age-dependent decline in PV expression outlined in Chapter
2, in Chapter 5 1 and 6 month old saline-control groups were compared, revealing a
marked (approximately 50%) decrease in HPC PV expression in 6 month compared to1
month old rats. This stark decrease in PV expression from 1 to 6 months, in conjunction
with the age-related decreases presented in Chapter 2, provide compelling evidence for
natural alterations in PV expression across development. The consistency of this finding
across multiple studies in our lab suggests that this age-dependent decline is robust
and brain-region specific, and should therefore be considered when developing and
interpreting models of putative neural pathology.
6.2.1 Hippocampal parvalbumin expression
The HPC structure is integral for cognitive processing and memory formation within the
109

brain (Milner et al., 1998), and can be divided along its septotemporal axis into three
distinct regions (Amaral & Witter, 1989). Septal, MST, and temporal regions of the HPC
are thought to be differentially associated with distinct roles in information processing,
with septal regions receiving spatial and sensory information, while temporal regions are
associated with emotionally salient content (Bannerman et al., 2004). Due to the
differences in the type of information processed, as well as overall differences in
functionality, it follows that anatomical markers might also vary as a function of
septotemporal location (Gusev et al., 2005). The distribution of PV expression across
the long axis of the HPC are not well documented in the literature, and only a small
number of studies (the present work included) detail changes in expression across the
entirety of the HPC. Nomura and colleagues (1997) characterized PV expression across
the septotemporal axis of young rats, and found no difference in PV expression as a
function of septotemporal location. This finding is replicated within the current work, as
we describe a lack of septotemporal variation across all HPC sub-regions in 1 month old
animals (see Chapter 2). However, to our knowledge, there has been no systematic
evaluation of PV expression across the septotemporal axis in adult and/or aged rats. To
this end, the present work carried out in Chapter 2 of this dissertation provides clarity to
the literature, detailing that 6 and 12 month old behaviorally naïve rats show a selective
decrease in PV expression across the CA1 long axis, such that septal regions of CA1
have an elevated number of PV expressing cells compared to MST and temporal
regions, with stable septotemporal distribution within CA3 and DG (refer to Figure 2.7).
In terms of age-dependent changes in PV expression within the HPC, we see a
general decrease in PV expression in 6 and 12 month old rats compared to 1 month old
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rats, with expression remaining stable between these later time points. This finding
suggests that PV expression is initially high in young rats, and then decreases in
adulthood; therefore PV likely changes as a function of neural development. These
findings are consistent with preliminary findings in our lab as previously described
(Corriveau, Master’s Thesis, 2013).Furthermore, the age-related decline seen in the
present work is in agreement with age-dependent changes in PV expression observed
by other groups (e.g., Shetty & Turner, 1998; Lee et al., 2008). Providing additional
support for age being a key player in PV expression, Chapter 5 presents evidence of a
decrease in PV expression in 6 month compared to 1 month old control rats. Generally,
we also describe a lack of additional decline in expression from 6 to 12 months of age,
indicating that PV expression appears to remain constant during adulthood. We propose
that this decrease may be due, at least in part, to pruning during the pubertal period,
and may be cell-type specific (Fish et al., 2014). However, further examination into this
phenomenon is necessary to pinpoint underlying mechanisms of protein expression
alterations due to aging.
6.2.2 Cortical parvalbumin expression
Generally, we found no significant effect of age on PV expression within any of the
neocortical or striatal regions of interest we examined across the present studies within
the following regions of interest: caudate, anterior cingulate, somatosensory barrel
fields, retrosplenial cortex, and ventral auditory cortex. However, we did observe one
instance where there was a significant decrease in PV expression in 6 month old rats
compared to 1 month old rats within the prefrontal (anterior cingulate) cortex (see
Chapter 5). Due to the fact that this decrease was only observed in a single study, it is
unlikely to be a stable age-related finding. This is especially true in light of the work
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conducted in Chapter 2, where there was a trend toward significance for 6 and 12
month old rats to have elevated PV expression compared to 1 month old rats. Likely, we
do not see significant changes in many of these cortical regions due to the early
maturation of inhibitory circuitries, compared to the slower maturation of circuits in areas
like the HPC (Bergmann et al., 1991) and the prefrontal cortex (Lewis et al., 2004;
Crews et al., 2007), and therefore the treatment windows employed in the current work
may not encompass critical windows of circuit development.

6.4

Effects of chronic ketamine administration on behavior and neuroanatomy

6.4.1 Effect of chronic ketamine on radial water maze performance
Chronic KET administration had a clear impact on cognitive performance in the DMTSRWM task, which is evidenced in findings presented in Chapters 3 and 4 of this
dissertation (see Figures 3.2 and 4.2, respectively). In both studies, chronic KET
administration significantly impaired performance, such that KET treated rats committed
significantly more errors when attempting to find the goal location than saline controls.
In Chapter 3 KET treated rats also displayed a lasting effect of treatment up to 3 days
post drug-cessation, indicating that the impact of chronic KET on cognition may be due,
at least in part, to underlying changes in neural pathology (Morgan et al., 2004).
Impairment on performance within this task suggests that chronic KET administration
interferes with cognitive processes integral to spatial memory and temporal dissociation
of goal representations (Chrobak et al., 2008), therefore creating increased instances of
proactive interference similar to that seen in SCZ patients (Barch & Smith, 2008).
Interestingly, we describe a differential effect of chronic KET treatment with
regard to age and behavioral experience as evidenced in Chapters 3 and 4. Specifically,
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in Chapter 3, we describe a significant KET-induced impairment in cognitive
performance in 6 month old adult rats, with no parallel changes in average PV
expression compared to saline controls. In Chapter 4, we also describe a significant
KET-induced impairment in cognitive performance in the DMTS-RWM task in 2-3 month
old adolescent rats, in addition to a marked concomitant decrease in PV expression in
KET compared to saline treated rats. These findings, when considered together, provide
compelling evidence for an age-dependent interaction with chronic KET treatment on
PV expression, indicating that young rats (2-3 months) appear to be more vulnerable to
KET-induced cognitive impairment, in addition to more sensitive to the deleterious
impact of KET treatment on PV expression, specifically within HPC CA1.
6.4.2 Effect of chronic ketamine on parvalbumin expression
6.4.2.1

Hippocampal parvalbumin expression

In the present set of studies, the impact of chronic KET administration varied as a
function of age and, to a certain extent, behavioral experience on PV expression within
the HPC formation. In Chapter 3, we describe no significant effect of chronic KET
administration within any of the HPC sub-regions in adult rats. However, this is likely
due to the advanced age (6 months) of the rats, as younger (2-3 month old) KET treated
rats showed a significant decline in PV expression within the HPC. This indicates that
PV is likely more vulnerable in young rats, thereby making chronic KET treatment more
impactful on both cognition and neuroanatomy.
In agreement with the findings from Chapters 3 and 4, Chapter 5 details findings
indicating that 6 month old rats receiving chronic KET administration did not generally
show changes in PV expression within the HPC, with the exception of the DG, where
there was a significant increase in PV expression following KET treatment. In contrast,
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we provide compelling evidence for a robust and significant KET-induced decrease in
PV expression within 1 month old behaviorally naïve rats. The reduction in PV
expression is nearly 30% in KET treated groups across all regions of the HPC in 1
month old rats, and this reduction stays consistent regardless of time of sacrifice,
indicating a long-term effect of chronic KET treatment on underlying neural pathology.
The fact that we see such a robust reduction in PV expression in 1 month old rats, but
not 6 month old rats, following chronic KET administration within the HPC is novel, and
suggests that KET may be interacting with PV expressing neurons in different ways
based on age and age-related changes in PV-localized NMDA receptors (Cull-Candy et
al., 2001). This differential effect speaks to the overwhelming need to control for
developmental age when utilizing NMDA hypofunction preparations, as age is a critical
factor in normative PV expression.
6.4.2.2

Cortical parvalbumin expression

Generally, within the neocortical regions of interest (prefrontal/cingulate cortex,
retrosplenial cortex, and somatosensory barrel cortex), there were no significant effects
of KET administration. In Chapters 3 and 4, there are no significant effects of chronic
KET treatment on PV expression within the neocortex. Additionally, in Chapter 5, there
was no effect of KET administration on cortical PV expression in 1 or 6 month old rats.
This indicates that cortical regions appear to be resilient to the deleterious effects of
NMDA hypofunction induced by chronic KET treatment, regardless of age and
experience. The lack of a KET-driven effect on PV expression in the neocortical regions
is likely due an advanced and early maturation in these areas compared to HPC
regions, where we see increased susceptibility (Yu et al., 2006).
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6.5

Future directions

While the present set of studies provides clarity to the literature, additional research is
warranted to further investigate and elucidate upon the findings presented herein. With
regard to the significant age-dependent reduction in PV expression across
development, it would be useful to further characterize the developmental shift in PV
expression across the entire lifespan of the rat. Such a study would provide much
needed characterization of the dynamic role of age in overall PV expression, and would
allow for researchers to pinpoint, more precisely, the time course during which PV
begins to decline toward adult levels from initial elevated baseline adolescent
expression.
Further characterization of the impact of enrichment is also an avenue for future
research, as the present, and previous (e.g. Corriveau, Master’s Thesis, 2013), work
provides evidence for a mediating effect of behavioral training on PV expression. While
the present studies suggest an upregulation in PV expression based on behavioral
training consistent with previous work (Corriveau, Master’s Thesis, 2013), it is unclear
whether similar training, or minimally early-life enrichment, in very young (<1 month)
would elicit a similar result. Such a study could provide evidence for behavioral
interventions early on in life to buffer the deleterious effects of insults – whether they be
in the form of NMDA hypofunction or otherwise – later in life. Overall, these proposed
studies would allow for systematic and thorough investigation into key factors we have
shown to be integral in the dynamic regulation of PV expression within the rat brain.
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6.6

Final conclusions

Taken together, the current body of work provides a comprehensive characterization of
the dynamic impact of age, behavioral experience, and chronic KET administration on
PV expression within the rat brain. Our findings provide a solid foundation for future
work detailing a time-line of PV expression across multiple developmental time points,
in addition to providing a framework for understanding the role of age and chronic
NMDA hypofunction on PV immunoreactivity. Our findings provide timely and
compelling evidence for a significant role of age in PV expression within the HPC that
should be carefully considered when modeling SCZ pathology, as this factor markedly
modulates PV. Importantly, the current findings contained in the present dissertation,
and those we have proposed, allow for enhanced understanding and interpretation of
future studies aiming to understand the dynamic relationship between PV expression
and SCZ cognitive dysfunction. Overall, the present work in this dissertation present
clear evidence that PV expression is mediated by a myriad of influences, and thus may
not be an accurate marker of pathology due to the dynamic nature of its neuronal
expression, as well as its unclear relationship to cognitive dysfunction.
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